Leveraging human induced pluripotent stem cells for modeling brain diseases by Lendemeijer, B. (Bas)
Leveraging human induced pluripotent 




Cover shows a co-culture of induced pluripotent stem  
cell derived astrocytes (green/red) and neurons (cyan)
Printing: Ridderprint B.V., Ridderkerk
Design: Le concepteur
Copyright © 2021 B. Lendemeijer
All rights reserved. No parts of this publication may be reproduced, stored in a retrieval 
system or transmitted in any form without permission of the author or, when appropriate, 
the scienctific journal in which parts of this thesis have been published.
Leveraging Human Induced Pluripotent 
Stem Cells For Modeling Brain 
Diseases
Het gebruik van menselijke geïnduceerde  
pluripotente stamcellen om hersenziekten  
te modelleren 
Thesis
to obtain the degree of Doctor from the
Erasmus University Rotterdam
by command of the rector magnificus
Prof. dr. A.L. Bredenoord
and in accordance with the decision of the Doctorate Board.
The public defence shall be held on
Tuesday October 5th, 2021 at 13:00 hours
by
Bas Lendemeijer
born in ‘s-Hertogenbosch, The Netherlands.
4
Promotors: prof. dr. S.A. Kushner
prof. dr. W.J.G. Hoogendijk
Other members: prof. dr. E.M. Hol
dr. N. Nadif Kasri
dr. G.M. van Woerden





List of abbreviations  
 
Preface
Scope of this thesis 
Chapter 1: General introduction 
Chapter 2: Rapid specification of human pluripotent stem cells  
to functional astrocytes supporting neural network activity 
Chapter 3: In vivo preclinical screening of human antisense  
oligonucleotide therapy for Angelman Syndrome 
Chapter 4: Candidate CSPG4 mutations and induced pluripotent stem cell  
modeling implicate oligodendrocyte progenitor cell dysfunction in familial 
schizophrenia 
Chapter 5: Replication kinetics, cell tropism and associated immune responses  
in SARS-CoV-2 and H5N1 virus infected human induced pluripotent stem  
cell-derived neural models 
Chapter 6: General discussion  
Appendices
Summary   
Samenvatting   
Curriculum Vitae   
PhD portfolio   
List of publications 



































Promotors: prof. dr. S.A. Kushner
prof. dr. W.J.G. Hoogendijk
Other members: prof. dr. E.M. Hol
dr. N. Nadif Kasri
dr. G.M. van Woerden
Co-promotor: dr. F.M.S. de Vrij

7
List of abbreviations 
ACE2   Angiotensin-converting enzyme 2
AS   Angelman syndrome
ASO   Antisense oligonucleotide
BoC   Brain on a chip
CNS   Central nervous system
CNV   Copy number variants
CRISPR   Clustered Regularly Interspaced Palindromic Repeats
CSF   Cerebrospinal fluid
CSPG4   Chondroitin Sulfate Proteoglycan 4
Dup15q   15q11-q13 duplication syndrome
ESC   Embryonic stem cell
EB   Embryoid body
GWAS   Genome wide association study
sgRNA   Single-guide RNA
ICV   Intracerebroventricular  
iPSC   Induced pluripotent stem cell
MAF   Minor allele frequency
MEA   Multi-electrode array
MEF   Mouse embryonic fibroblast
NB   Network burst
NDD   Neurodevelopmental disorder
NG2   Neural/glial 2
Ngn2   Neurogenin-2
NHEJ   Nonhomologous DNA end joining
NPC   Neural precursor cell
NRP1   Neuropilin-1
OPC   Oligodendrocyte precursor cell
OSVZ   Outer subventricular zone
PWS   Prader-Willi syndrome
SARS-CoV-2  Severe Acute Respiratory Syndrome Coronavirus-2
TMPRSS2  Transmembrane protease serine 2
WTC   Wild-type control




In 2007, Shinya Yamanaka published his seminal paper1 describing a technique to create 
induced pluripotent stem cells (iPSC) from human fibroblasts. The possibility to convert 
terminally differentiated somatic cells into iPSCs has changed the way human disorders are 
studied, especially in the field of neuroscience. Primary ex vivo human brain tissue is very 
scarcely available. Generally speaking, post-mortem human brain tissue is more readily 
available, though still in short supply. This has been a major constraint when studying the 
human brain, both in a healthy and diseased state. The molecular and functional properties 
of human neural cells could only be studied using post-mortem or ex-vivo material. By 
using model organisms, much has been learned normal brain development and functioning. 
Animal models have been established for various psychiatric and neurodevelopmental 
disorders, and, together with postmortem human studies, have provided some insight 
into the etiology of these disorders. However, this increase in knowledge has not led to 
an improvement in treatment options. By utilizing iPSC technology, it is now possible 
to create patient-derived iPSC lines and study their development and maturation along 
defined neural cell type lineages. For the first time providing researchers with a potentially 
unlimited source of human neural cells to study. Early work has shown the potential of 
this approach for modelling psychiatric and neurodevelopmental disorders, providing novel 
insights and revealing important differences between mouse and human neural cells. 
Since the establishment of this technique, iPSC-derived neural cells have evolved from 
neurons that are able to fire a single action potential to brain organoids that display waves 
of electrical activity. The rapid evolution of this field continues to entice researches to adopt 




Scope of this thesis
IPSC technology can be used to study the development of all cell types of the human body 
in health and disease, this work describes how this technique can be utilized to study human 
brain disorders. Chapter 1 attempts to provide an overview of the current state of the field 
and how iPSCs can be leveraged to study the functioning of healthy and diseased human 
brain cells. Chapter 2 describes a novel protocol to rapidly differentiate human iPSCs into 
functional astrocytes that have been validated to support neural maturation, a feature for 
which an adequate iPSC-differentiation protocol has not been reported yet. An in vivo model 
to explore a potential human specific treatment for Angelman syndrome (AS) is presented in 
Chapter 3. AS patient-derived neurons are xenografted into a mouse brain and exposed to 
human-specific antisense oligonucleotides in order to restore the expression of the disease-
causing gene. The potential of using iPSCs to study psychiatric disorders is illustrated in 
Chapter 4, in which we demonstrate that iPSC-derived oligodendrocyte precursor cells 
from schizophrenia patients carrying a rare CSPG4A131T mutation show reduced viability and 
impaired maturation potential towards myelinating oligodendrocytes. Chapter 5 describes 
how different iPSC-derived neural culture models can be used to study the replication 
kinetics and cell tropism of the novel Severe Acute Respiratory Syndrome Coronavirus-2 to 
investigate a possible link between infection in the central nervous system and neurological 
symptoms observed in patients. Finally, Chapter 6 places the work described in this thesis in 
a wider context, describes technical considerations when working with iPSCs and possible 





Studying the human brain 
The human mind is a mysterious concept. However, there is broad consensus that it originates 
from the 170 billion cells in the human brain, divided nearly equally between neuronal and 
non-neuronal cells2. Animal models have provided insight into some features of the brain. 
For example, we know how location3 or visual information4 is processed. Unfortunately, this 
increase in knowledge hasn’t led to improved treatment for patients suffering from psychiatric 
or neurodevelopmental disorders (NDD). At present, we still do not fully understand why 
some people develop psychiatric symptoms and others do not. The frustrating reality is that 
no significant progress in psychiatric drug development has been achieved during the past 
50 years5,6,7.  For some NDDs, the causal genetic variant has been identified8, however for 
most NDDs the cellular etiology remains elusive.  Generally speaking, few risk variants have 
been identified for psychiatric disorders. Large genome wide association studies (GWAS) 
have identified genetic variants associated with psychiatric disorders, these common 
variants contribute only slightly to the chance of developing the disorder9,10. Other studies 
have identified rare (copy number) variants11,12 with a large effect on psychiatric disease 
risk, however, these variants explain only a small proportion of cases and most include 
large genomic regions with multiple genes, which can be difficult to study in non-human 
model systems as a result of genomic divergence. Heterogenous diagnostic criteria make 
it challenging to establish defined patient groups, and combined with environmental risk 
factors complicate the identification of genetic variants even further13. 
Without a clear genetic or environmental causal defect, the classical approach of studying 
human disorders through animal models is complicated. As an alternative approach, drugs 
that act on neurotransmitter systems in the brain have been used to mimic psychotic 
symptoms in animals14, providing a platform to study specific aspects of psychiatric disorders. 
Even when the exact genetic cause for a NDD is known, mouse models often fail to fully 
recapitulate the symptoms observed in patients. Moreover, drugs that effectively rescue 
phenotypes in an animal model frequently fail to translate to the clinic15. Most of these 
models rely on a single affected gene in an inbred genetic background, of which some only 
show a relevant phenotype in specific mouse strains. In contrast, patients can carry multiple 
genetic variants16, and the phenotypic expressivity is an interplay between individual gene 
vulnerability and total mutational load17. Besides the genomic differences in animal models 
and humans, there are also fundamental species differences in neurodevelopment and 
pathology, especially when compared to the widely used rodent models. 
The evolution of the mammalian cortex is considered to be one of the key features that 
enabled the development of higher cognitive functioning. Neocortical development is 
well studied in rodents, which share fundamental characteristics with other mammals, 
including cortical layering and topographic separation into functional domains. During 
brain development, mice and humans share many features and undergo a similar order 
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of developmental events18. Both species have homologous neural cell types and utilize 
similar cellular or molecular processes, making them an excellent model organism to study 
some aspects of the brain. Often these findings translate well to the human brain. However, 
striking differences exist in the development of the rodent and human cortex. The cortex 
of mice is small and smooth, whereas the human cerebral cortex shows a high amount 
of folding, known as gyrification19. This difference originates from the outer subventricular 
zone (OSVZ). During the second half of human cortical development, the OSVZ is the 
major neurogenic region 20, a region that does not exist in the mouse brain, including the 
resident stem cells. This subpopulation of neural stem cells in the OSVZ is essential for 
the development of large and gyrated brains21. Increases in cortical volume and surface 
area have been causally linked to the proliferation and migration of OSVZ cells22. This 
fundamental difference in cortical development and structure make mice less suitable for 
studying many complex features of cerebral cortex development, and consequently, higher 
cognitive functioning. 
Besides anatomical differences, conserved cell types between species differ in their 
expression profile23 and morphology24.  A recent study23 examining the expression profile 
of individual cells in the human and mouse middle temporal gyrus found that roughly 
two-thirds of all genes analyzed had divergent expression in at least one of the cell types 
identified, with non-neuronal cells showing the highest amount of divergent expression. 
For example, 14% of genes analyzed in oligodendrocyte precursor cells (OPC) showed a 
more than 10-fold difference in gene expression when comparing human and mouse brains. 
The biggest cellular differences between the mouse and human brain can be found in the 
astrocyte lineage. Human astrocytes are larger and more complex compared to their mouse 
counterpart24. Interestingly, a specific subtype of interlaminar astrocytes is found exclusively 
in higher order primates25. These cells have long projections covering all layers of the cortex 
and are hypothesized to govern neuronal activity across cortical layers. A mutation in a gene 
highly expressed in interlaminar astrocytes has been associated with major depressive 
disorder, a uniquely human disorder26. 
Induced pluripotent stem cell derived neural models
The molecular, cellular and anatomical differences between mouse and human brains 
combined with a lack of successful translational studies in the field of neuroscience 
motivated researchers to look for new models to study human brain development. In an 
effort to understand the molecular cues involved in the formation of the human brain, early in 
vitro work made use of embryonic stem cells (ESC)27 or primary neural stem cells28,29. These 
studies were hampered by ethical concerns and the limited availability of primary ex vivo 
brain tissue. In 2007, the lab of Shinya Yamanaka published a pioneering paper1 describing 
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a technique to transform terminally differentiated somatic cells into induced pluripotent stem 
cells (iPSCs). These cells share many of the hallmark features of ESCs, including the potential 
to differentiate into cells from all three germ layers. Somatic cells, usually blood or skin, are 
reprogrammed into iPSCs trough overexpression of four transcription factors (Oct3/4, Sox2, 
Klf4 and L-Myc), now referred to as the “Yamanaka factors”. With the establishment of this 
technique, researchers now had access to a potentially unlimited source of ESC-like cells 
to study human developmental biology and disease. When expressed in somatic cells the 
Yamanaka factors induce a cascade of events, remodeling the epigenetic landscape of 
cells and activating genes essential for inducing and maintaining pluripotency30. Since the 
establishment of this technique, high variability between iPSC clones due to reprogramming 
and quality control differences has been an issue31, however, the same can be said for 
ESCs32. A study comparing genetically matched iPSCs and ESCs found that the majority 
of gene expression and methylation differences could be explained by genetic background 
and not reprogramming method or cellular origin33, suggesting that iPSCs are functionally 
identical to ESCs and a suitable tool to study the development of patient-derived cell types. 
With the advent of iPSCs, it became possible to study the molecular and cellular development 
and maturation of human brain cell lineages in the context of the human genome. Scientists 
studying neuropsychiatric disorders now had access to human pluripotent stem cells 
harboring the genome of pathogenic variant carriers. These cell lines could be used to 
observe and manipulate the development of neural lineage cells cultured in vitro. The 
identification of the pathophysiology of psychiatric and neurodevelopmental disorders 
has historically been difficult due to a lack of suitable experimental tools and the species 
differences between humans and experimental animals. IPSC technology presents unique 
opportunities to address both of these challenges. 
Numerous protocols exist to establish neural cultures from iPSCs with different cell type 
composition and levels of maturity. Some result in a mixed population of different neural 
cells, while others give rise to a homogenous culture of a single cell type or free-floating 
3D brain organoids. Since most are costly and labour intensive, it is crucial to consider 
the differences between the resulting neural cultures before deciding whether a certain 
protocol is relevant for answering a particular question or hypothesis. Broadly speaking, 
differentiation protocols can be divided into two groups – one approach follows a more 
endogenous physiological differentiation process involving neural precursor cells (NPCs) 
differentiated from iPSCs through an embryoid body34,35 or dual SMAD inhibition36 stage, 
and subsequently differentiating these NPCs into neural cultures which typically contain a 
diverse mixture of neural cell types. Alternatively, it is possible to establish a pure culture 
of a specific neural cell type through forced overexpression of lineage-specific transcription 
factors in iPSCs or NPCs (Figure 1.1). Microglia, the resident immune cells of the central 
nervous system (CNS), originate from the mesoderm and thus need to be differentiated 
through an intermediate hematopoietic progenitor stage37. 
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Figure 1.1: A simplified schematic of the approaches to obtain different neural cell types. Neural 
induction through defined cell culture media follows a more natural approach by mimicking embryonic 
development, depicted left to right. iPSCs are exposed to growth factors that induce the formation 
of cells from the ectoderm lineage, followed by NPCs and finally terminally differentiated neural 
cells. Depending on the desired cell type and brain region the media composition can be adjusted. 
Alternatively, it is possible to create a relatively homogenous population of the desired cell type through 
forced overexpression of certain lineage-specific transcription factors, depicted top to bottom. 
Mixed neural cultures derived from NPCs have the advantage that glia and neurons develop 
side-by-side in the same culture in an important reciprocal balance. Neural network protocols 
are available to generate cultures with different regional specificities, for example, midbrain 
dopaminergic neurons38 or forebrain glutamatergic neurons35. These mixed cultures give 
rise to functionally mature neural networks without the need for specialized media or the 
supplementation of (rodent) astrocytes. Neurons in such a culture typically express the 
canonical neuronal markers, form functional synapses and show spontaneous network 
activity. However, differentiation of neural cultures from iPSCs through an NPC stage is time 
consuming. Protocols typically require 2-3 months before neurons are considered mature 
and able to fire repetitive action potentials. However, there is a distinct advantage to this 
approach when studying the effect of certain compounds and/or genetic background at 
different stages during neurodevelopment. For example, potential phenotypes at the NPC 
Neural induction through growth factors
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stage might be masked when using trans-differentiation to direct iPSCs into a single desired 
cell type39. Molecular and cellular processes that are essential during NPC differentiation 
are bypassed when directly differentiating iPSCs to mature neural cells.
Trans-differentiation, also known as forward programming, is a rapid method to obtain a 
homogenous and differentiated culture of a desired cell type from iPSCs. Through forced 
overexpression of specific transcription factors, iPSCs change their gene expression profile 
and differentiate towards a specific cell type. Established protocols exist for neurons40,41, 
myelinating oligodendrocytes42 and astrocytes43. With this approach, it is possible to obtain 
terminally differentiated cells from iPSCs or neural precursors within 3 weeks, significantly 
reducing the required time investment compared to traditional differentiation through an 
embryoid body stage. However, to fully mature the cells, a co-culture system is required. 
Neurons are unable to form electrically active networks in the absence of astrocytes. 
Oligodendrocytes will not produce myelin in the absence of axons and astrocytes only 
express a subset of mature markers in the presence of neurons. 
Forced overexpression of Neurogenin 2 (Ngn2) in iPSCs gives rise to mature excitatory 
neurons when grown in a co-culture with primary rat astrocytes44. Using multi-electrode 
arrays, it is possible to record the electrical activity of these Ngn2-neurons, making it possible 
to efficiently investigate the effect of compounds or genetic variants on the functioning of 
neurons at a relatively large scale. Ngn2-neurons have also been transplanted into the 
rodent brain40 to study drug effects on human neurons in an in vivo environment. Forward 
programming of iPSCs to oligodendrocytes is achieved by overexpression of SOX10 in 
OLIG2+ glial precursors, giving rise to O4+ oligodendrocyte lineage cells that induce 
myelination when grown in the presence of neurons. These cells can be used to create a 
highly scalable platform to study the effect of pro-myelinating compounds45. A pure astrocyte 
culture can be obtained through forced overexpression of SOX9 and NFIB in NPCs. This 
method is faster compared to traditional approaches for deriving astrocytes using growth 
factors and specialized media, however, these astrocytes have thus far shown limited 
functionality and have not been capable of supporting the development and maturation 
of neural networks43. In an effort to address this technical limitation, Chapter 2 describes 
a novel protocol to obtain a homogenous culture of iPSC-derived astrocytes that are able 
to promote the development and maturation of neural networks. With these techniques, 
scientists now have access to a pure population of all major cell types in the brain, making it 
possible to precisely titrate the cellular composition of human neural co-cultures.
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Developing treatment for human  
neurodevelopmental disorders
The major advantage of studying human neural cells is the ability to investigate the effect 
of compounds or genetic variants in a fully human background. As mentioned earlier, some 
developmental and cellular aspects of the human brain are simply not present in animal 
models. Moreover, there is a safety aspect involved when advancing to clinical trials. The 
importance of this was recently highlighted when one volunteer died and four others suffered 
irreversible brain damage during a phase I first-in-human clinical trial for a fatty acid amide 
hydrolase inhibitor, BIA 10–247446, a compound developed to alleviate neuropathic pain. 
Standard safety trials preceding clinical trials showed no adverse side effects in mice, rats 
or dogs, while macaques exposed to a high dose showed damage in the medulla oblongata. 
Later it was shown using in vitro human models that the compound had off-target effects not 
detected in rodents47. This tragic incident led to renewed consideration of preclinical testing 
requirements prior to regulatory approval for new drug entities and corresponding clinical 
trial safety standards46,48,49.
An emerging treatment option for human disorders with a known genetic defect is the 
modality of antisense oligonucleotides (ASO), which can be designed to potently reduce or 
modify translation from specific RNA transcripts50,51. ASOs are short single-stranded DNA 
sequences that are able to bind RNA transcripts and, depending on the binding-location, 
induce RNA breakdown or splicing modification. Since the target for these ASOs are human 
transcripts, the sequence is often non-specific in mouse models. Clinical trials using ASOs 
have already been completed, for which the most notable successes have been for the 
treatment of spinal muscular atrophy52 and Duchenne muscular dystrophy53. A recent proof-
of-concept study demonstrated that ASOs designed to target a patient-specific sequence 
could be used to treat a rare and fatal NDD54, such an approach is unsuitable for traditional 
clinical trials due to its “N-of-1” design. Despite these early successes, concerns exist about 
the safety of ASOs55. Designing and testing novel ASOs is a time-consuming process, 
for which the efficacy of ASO sequences and chemical backbones need to be tested and 
screened for toxicity. Human cell culture models can be used to test the efficacy of an 
ASO. However, given the potential clinical therapeutic utility of ASOs, an in vivo preclinical 
model would be preferable to exclusively relying upon human cells in vitro. Moreover, in 
vivo delivery of ASOs for the treatment of central nervous system diseases is complicated 
by their very low permeability across the blood-brain-barrier, for which important successes 
have been achieved with intrathecal delivery of ASOs. 
Angelman Syndrome (AS) is potentially suitable for treatment with ASOs. It has a well-
established genetic cause through loss-of-function of the maternal copy of the UBE3A gene. 
AS patients suffer from severe neurodevelopmental delay, intellectual disability and motor 
problems56. Multiple mouse models have been created to study AS, which recapitulate the 
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molecular and cellular phenotypes in neurons and to some extent behavioral phenotypes 
in similar functional domains as observed in patients57. Reinstatement of Ube3a early in 
development can rescue behavioral phenotypes observed in an AS-mouse model58. During 
development, the paternal UBE3A allele is silenced in mature neurons due to transcription 
of a long non-coding UBE3A-antisense transcript, which blocks UBE3A-sense transcription. 
Targeted transcriptional blockade of this paternal antisense transcript using Cas9 gene 
therapy successfully reactivated maternal UBE3A expression in cultured human neurons 
and a mouse model for AS59. ASO therapy targeting the UBE3A-antisense transcript also 
restored paternal UBE3A expression at an early age, a modality that could potentially 
be used to treat children even before symptoms arise. A model mimicking a potential 
therapeutic approach for AS  is described in Chapter 3, in which AS patient-derived neurons 
are transplanted into mouse brains, and subsequently treated by intraventricular injection 
with a human-specific ASO, designed to target the human UBE3A-antisense transcript.
Studying schizophrenia using induced pluripotent stem cells
Studying the cellular underpinnings of psychiatric disorders is challenging. Animal models 
fail to fully recapitulate the phenotype observed in patients. Moreover, they are limited 
in their ability to reveal fundamental human genetic and cellular processes. Although we 
have learned much from animal models, there is still a substantial amount that we do not 
understand about psychiatric disorders60. The importance of studying human disorders on 
a human genetic background is highlighted in Chapter 4. A family-based genetic study 
identified two rare missense mutations in Chondroitin Sulfate Proteoglycan 4 (CSPG4)11, 
one of which is the reference sequence in the mouse genome. CSPG4 codes for a protein 
known as neural/glial 2 (NG2), one of the hallmark proteins of OPCs, also known as NG2-
cells. OPCs derived from iPSCs generated from carriers of the identified CSPG4 mutation 
show aberrant NG2 processing, reduced proliferation and are less likely to mature to 
myelinating oligodendrocytes. 
Schizophrenia is a debilitating disorder affecting roughly 1% of the general population 
worldwide61. Symptoms include positive symptoms (i.e., hallucinations or delusions), 
negative symptoms (i.e., diminished emotional expression or avolition)62 and cognitive 
symptoms. Patients are often profoundly affected and require extensive care from health 
care professionals. The chronic nature of the disorder creates a significant burden on 
patients, their families and society. In the Netherlands, the yearly costs associated with all 
forms of psychiatry-related treatment were roughly 40.000 euros per patient between 2009 
and 201263. Besides the costs associated with care, European studies report that 80-90% of 
patients with schizophrenia are unemployed64. More effective treatments for schizophrenia 
with diminished side effect burdens would greatly improve the quality of life for patients 
and potentially reduce the cost for society. Currently, lifelong treatment is required, even 
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when a patient is not experiencing a psychotic episode65. We do not have a satisfactory 
understanding of the pathophysiology of schizophrenia. Moreover, while we recognize 
many of the symptoms of schizophrenia, our current diagnostic classification is qualitative 
and descriptive, rather than quantitative and based on objective laboratory testing.
The dopamine system is believed to be involved in the pathogenesis of schizophrenia, due 
to the canonical mechanism of all known antipsychotics – antagonism of dopamine D2 
receptors6,7. Moreover, recreational drugs, such as amphetamines, act directly or indirectly 
as dopaminergic agonists and are known to induce psychosis in some individuals66. People 
suffering from schizophrenia seem to be more susceptible to these effects67, a finding which 
has been cited to support the “dopamine hypothesis” of schizophrenia68 and sparked decades 
of research into neurotransmitters and brain regions potentially involved in schizophrenia 
and psychosis more generally. Broadly speaking, the current working hypothesis of 
schizophrenia postulates that dopamine is dysregulated in two different systems. Negative 
symptoms are attributed to hypoactive dopamine receptors in the prefrontal cortex, whereas 
psychotic symptoms are believed to be caused by hyperactive dopamine receptors in the 
limbic regions of the brain. Psychosis is thought to arise from dysregulated dopamine signaling 
in the striatum, leading to the improper attribution of salience to certain external stimuli69.
The modulation and organization of neuronal networks is heavily influenced by glia. 
Oligodendrocytes70 and astrocytes71–73 govern network activity and integrate neuronal activity 
in order to ensure proper synchronization between higher order brain functions. Glia have 
long been considered to play a part in the pathophysiology of schizophrenia74–76, although 
their exact contribution remains unknown. RNA sequencing and GWAS findings suggest 
dysregulated expression of genes related to schizophrenia risk in glia.77–80 Specifically, 
these studies indicate changes in expression among schizophrenia patients during brain 
development, related to white-matter abnormalities, neuroinflammatory pathways and 
upregulation of astrocyte-specific genes.
Oligodendrocytes ensheath the axons of neurons with a dense lipid-rich membrane 
called myelin, together also known as the white-matter of the brain. Astrocytes influence 
the maturation of oligodendrocyte precursor cells into oligodendrocytes and subsequent 
myelination81. Proper myelin ensheathment is essential for saltatory conduction of action 
potentials82. Patients typically experience their first psychotic episode during adolescence, 
a time period that coincides with a peak of myelin and synapse remodeling in the brain83. 
However, throughout life myelination is a dynamic process, exhibiting plasticity of white-
matter microstructure during specific forms of learning84,85. Schizophrenia patients have a 
reduced number of oligodendrocytes in some brain areas83,86 and altered mRNA expression 
of oligodendrocyte and myelin-related genes87,88. Furthermore, white-matter abnormalities 
precede the clinical presentation of schizophrenia in some patients, and these abnormalities 
become more severe over the course of the disorder89. 
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Following the onset of psychosis, schizophrenia patients exhibit reduced white-matter 
integrity, most notably in the frontoparietal tract90. Patients that suffer from disorders affecting 
white matter integrity, such as leukodystrophies, can experience psychotic episodes91. 
These diseases have a diverse underlying etiology, but ultimately lead to defects in myelin 
development or maintenance. It is hypothesized that improper glial cell progenitor maturation 
leads to defects in oligodendrocyte and astrocyte functioning, and ultimately schizophrenia 
by disruption of synaptic connectivity, including alterations in dopaminergic signaling92.
Our knowledge of the neurobiology of schizophrenia has improved greatly over the past 
several years, however this has not led to improved treatment options for patients. There is 
a gap in our understanding about how the biological alterations we observe in patients give 
rise to their symptoms. For example, we know that schizophrenia patients have reduced 
white-matter integrity, but we do not know why this leads to schizophrenia or the underlying 
cellular mechanisms. Part of this knowledge gap can be explained by phenotypic and 
genetic heterogeneity among schizophrenia patients. Disease onset, progress, severity and 
symptoms can vary greatly among patients61. Early twin studies estimated the heritability 
of schizophrenia to be around 80%93,94. Despite significant effort in the field, only a small 
portion of this heritability can be accounted for by genetic variants9,95. IPSC technology aids 
in circumventing this problem. By creating patient-derived iPSC lines, the total genetic risk 
of individual patients is preserved, thereby providing a platform to study pathological cellular 
phenotypes originating from a patient-specific genetic background. However, without a 
clear hypothesis of the expected cellular phenotype, this approach can be problematic. 
Studying rare highly penetrant variants provides the ability to formulate hypotheses 
based on coding variants, which at present is more straightforward than interpretation of 
GWAS loci of small effect. Through modern genome editing, such as Clustered Regularly 
Interspaced Palindromic Repeats-associated nuclease Cas9 (CRISPR/Cas9)96, iPSC-lines 
from patients can be used to investigate the biological consequences of these variants 
compared to reference lines with an identical genetic background.
Neural cell tropism of emerging viruses
IPSC-derived neural cells have been shown to successfully model the kinetics and cell 
tropism of viruses causing neurological symptoms in humans. In early 2015, zika virus 
(ZIKV) caused a widespread epidemic in South America. ZIKV is a mosquito-borne virus 
first identified in 1947. Before this recent widespread outbreak, ZIKV had rarely been 
associated with human disease97. The strain responsible for the 2015 outbreak caused a 
range of neurological symptoms in patients, most notably, infection during the first trimester 
of pregnancy appeared to cause microcephaly or miscarriage98. IPSC-derived neural 
cultures showed that the 2015 pathogenic strain of ZIKV predominantly infected NPCs and 
induced cell death99, possibly explaining the observed microcephaly cases.
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The current outbreak of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2) was declared a pandemic on March 11th, 2020. Early reports of patients suffering 
from COVID-19, the disease caused by SARS-CoV-2, primarily reported symptoms related 
to the respiratory system100. Severe COVID-19 patients typically develop pneumonia or acute 
respiratory distress syndrome, with a current infection fatality rate estimated between 0.53%-
0.82%101. However, these estimates are based on a highly heterogenous patient groups and 
are likely to change as more data on the true caseload in the population becomes available. 
Besides respiratory symptoms, reports from patients suffering from neurological problems 
during or after COVID-19 have become more frequent102. Early reports state a high 
prevalence of anosmia and dysgeusia103,104. This does not seem to be associated with 
rhinorrhea as observed with rhinoviruses or other coronaviruses. In some cases, more 
severe neurological pathology have been reported, including cerebrovascular disease105, 
encephalitis106 and acute necrotising encephalopathy107. Following the immediate onset of 
COVID-19 symptoms, a proportion of patients experience long-term symptoms, referred to 
as Long COVID or Post-Acute Sequalae of SARS-CoV-2 Infection108. Patients experience a 
wide range of symptoms such as hair loss, muscular weakness or cognitive disturbances. 
However, the link between neurological symptoms and infection of the CNS is unclear. 
In the majority of COVID-19 fatalities, SARS-CoV-2 RNA or antigen cannot be detected 
in the brain109. In patients actively experiencing neurological symptoms, SARS-CoV-2 is 
also rarely detected in the cerebrospinal fluid110. Animal models have shown that SARS-
CoV-2 can infect and replicate in the olfactory mucosa and induce microglial recruitment, 
but convincing evidence of productive infection of olfactory neurons has not been found111. 
Together this suggests that SARS-CoV-2 might be able to enter the CNS through the 
olfactory nerve, as has been shown for other respiratory viruses112, but is not able to 
replicate efficiently within the CNS. It remains to be seen if observed neurological symptoms 
in patients are due to a primary infection in the CNS, secondary due to a heightened local 
immune response or a combination of both. Part of this question is answered in Chapter 
5. Different iPSC-derived neural cultures were used to investigate the kinetics, cell tropism 
and induced immune response of SARS-CoV-2 compared to the neurotropic virus H5N1 
influenza A.
Creating better models to study the development and functioning of defined human neural 
cell types will improve our understanding of their contribution to typical neurodevelopment 
and neuropsychiatric pathophysiology. Limited availability of primary ex vivo brain tissue 
remains an issue, but currently it is possible to create a potentially limitless amount of iPSC-
derived neural cells. Even though protocols have improved during the past decade, the field 
continues to be limited by technical challenges in directing the differentiation of brain cell 
lineages that recapitulate the physiology of fully mature in vivo cell types. Attempts to improve 
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Schizophrenia is highly heritable, yet its underlying pathophysiology remains largely 
unknown. Among the most well-replicated findings in neurobiological studies of schizophrenia 
are deficits in myelination and white matter integrity; however, direct etiological genetic and 
cellular evidence has thus far been lacking. Here, we implement a family-based approach 
for genetic discovery in schizophrenia combined with functional analysis using induced 
pluripotent stem cells (iPSCs). We observed familial segregation of two rare missense 
mutations in Chondroitin Sulfate Proteoglycan 4 (CSPG4) (c.391G > A [p.A131T], MAF 
7.79 × 10−5 and c.2702T > G [p.V901G], MAF 2.51 × 10−3). The CSPG4A131T mutation was 
absent from the Swedish Schizophrenia Exome Sequencing Study (2536 cases, 2543 
controls), while the CSPG4V901G mutation was nominally enriched in cases (11 cases vs. 
3 controls, P = 0.026, OR 3.77, 95% CI 1.05–13.52). CSPG4/NG2 is a hallmark protein 
of oligodendrocyte progenitor cells (OPCs). iPSC-derived OPCs from CSPG4A131T mutation 
carriers exhibited abnormal post-translational processing (P = 0.029), subcellular localization 
of mutant NG2 (P = 0.007), as well as aberrant cellular morphology (P = 3.0 × 10−8), 
viability (P = 8.9 × 10−7), and myelination potential (P = 0.038). Moreover, transfection of 
healthy non-carrier sibling OPCs confirmed a pathogenic effect on cell survival of both 
the CSPG4A131T (P = 0.006) and CSPG4V901G (P = 3.4 × 10−4) mutations. Finally, in vivo diffusion 
tensor imaging of CSPG4A131T mutation carriers demonstrated a reduction of brain white 
matter integrity compared to unaffected sibling and matched general population controls 
(P = 2.2 × 10−5). Together, our findings provide a convergence of genetic and functional 
evidence to implicate OPC dysfunction as a candidate pathophysiological mechanism of 
familial schizophrenia.
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Introduction
Schizophrenia is a severely debilitating psychiatric disorder affecting ~1% of the population 
worldwide171. The strongest known determinant for developing schizophrenia is family 
history. A meta-analysis which included five decades of twin studies concluded a heritability 
estimate (h2) of 0.77 ± 0.05, with a relatively limited contribution of shared environmental 
influences (c2) (0.013 ± 0.025)172.
The Psychiatric Genomics Consortium recently reported a genome-wide association study 
(GWAS) investigating 36,989 cases and 113,075 controls, in which 128 genome-wide 
significant single-nucleotide variants were identified across 108 independent genomic loci, 
suggesting an important contribution of common genetic variation to schizophrenia risk173. 
However, a large proportion of the heritability for schizophrenia remains unexplained, leaving 
many genetic variants remaining to be discovered. Therefore, increasing attention has also 
been focused on the potential contribution of rare genomic variation to schizophrenia risk. 
Copy number variants (CNVs) are a well established source of pleiotropic risk, ranging from 
asymptomatic carriership to a complex constellation of symptoms affecting multiple organ 
systems, such as the 22q11.2 microdeletion syndrome174. In a large-scale schizophrenia 
case-control cohort analysis, known pathogenic CNVs were significantly more frequent in 
cases (2%) than controls (0.4%)175,176. Moreover, an independent study found that large 
(>500kb) CNVs are enriched in loci associated with schizophrenia by GWAS and frequently 
involve genes encoding proteins located in the postsynaptic density177.
In addition to microarray-based genotyping methods, the development of next-generation 
sequencing has allowed the possibility to examine whether rare single nucleotide variants 
or small insertions-deletions contribute to schizophrenia risk. A Swedish cohort including 
2,536 cases and 2,543 controls yielded no single mutation or single gene reaching genome-
wide significance for association with schizophrenia, but confirmed a similar enrichment of 
gene sets for synaptic function as previously identified for genes located in schizophrenia-
associated CNVs and GWAS loci178. Moreover, trio-based studies have identified a number of 
candidate genes through identification of recurrent de novo mutations179,180 and an increased 
burden of mutations occurring in genes encoding glutamatergic postsynaptic proteins181.
Recent genetic and induced pluripotent stem cell (iPSC)-based studies have converged 
on a model by which neuronal function, and in particular synaptic transmission, is a major 
pathophysiological mechanism of schizophrenia34,173,178,181,182. However, functional neuronal 
alterations may arise either by direct cell-type autonomous changes to neurons themselves, 
or indirectly through a primary pathophysiological influence on other cell types that influence 
neuronal function. Numerous studies have reported the involvement of glial cell biology in 
the pathophysiology of schizophrenia, including alterations in oligodendrocytes, myelination, 
and white matter integrity183–188, which directly regulate neuronal function.
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Abnormalities of the integrity of the white matter are strongly associated with schizophrenia189. 
The late adolescent critical period for cerebral cortex myelination has long been recognized as 
overlapping closely with the typical age of onset for schizophrenia185,186. Myelination-related 
genes have been shown to be enriched for common variants associated independently 
to white matter integrity190 and schizophrenia184,191. Two recent brain imaging studies have 
elegantly compared white matter integrity in 16p11.2 deletion and duplication carriers192,193 
of which only the 16p11.2 duplication confers increased risk for schizophrenia176. Notably, 
both global fractional anisotropy and white matter volume were selectively decreased 
in 16p11.2 duplication carriers. However, despite increasing evidence of an association 
between schizophrenia and myelination integrity, the molecular and cellular mechanisms 
by which oligodendrocyte lineage dysfunction might influence schizophrenia risk have 
remained largely unknown.
We now report genetic and functional evidence of oligodendrocyte progenitor cell 
dysfunction in schizophrenia. Using a family-based genetic approach, we observed multiple 
rare missense mutations in CSPG4 that segregate with schizophrenia. Functional studies 
using iPSCs reprogrammed from affected CSPG4 mutation carriers and their unaffected 
non-carrier siblings revealed that patient-derived OPCs exhibit abnormal post-translational 
processing, aberrant subcellular localization of CSPG4/NG2, and abnormal cellular 
morphology. Moreover, diffusion tensor imaging of CSPG4 mutation carriers confirmed a 
global impairment in white matter integrity, together providing support for OPC dysfunction 
as a candidate pathophysiological mechanism of schizophrenia.
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Results
Genetic findings in the discovery family
A non-consanguineous family of Dutch ancestry was ascertained with a pattern of 
schizophrenia inheritance compatible with autosomal dominant transmission. The core 
pedigree consisted of a couple and their nine children (5 males, 4 females) of whom the father 
and 4 sons suffered from non-syndromic schizophrenia (Figure 4.1A and Supplementary 
Table 4.1).
Genome-wide parametric linkage analysis was performed on peripheral blood DNA using 
an autosomal-dominant, affected-only model of inheritance, in order to identify genomic 
regions shared among all affected family members (Supplementary Table 4.2). Whole 
exome sequencing was performed on three individuals of the family (pedigree IDs: II-2, III-5 
and III-9; Figure 4.1A). Five candidate heterozygous variants were identified based on the 
following criteria: a) located within the genomic regions shared among all affected family 
members, b) predicted to affect protein coding (missense, nonsense, frameshift, splice 
site), c) called in at least one of the affected individuals [III-5 and III-9], d) absent from the 
unaffected mother [II-2], e) absent from dbSNP129, and f) with a minor allele frequency 
(MAF) < 0.001 in the Exome Aggregation Consortium (ExAC) browser (Europeans non-
Finnish)194, EVS6500 European Americans, NHLBI Exome Sequencing Project (ESP)195, 
1000 Genomes196, and Genome of the Netherlands (GoNL)197 cohorts (Supplementary 
Table 4.3). Genotyping of these variants was performed by Sanger sequencing in all 
participating family members. 
Among the five candidate variants, CSPG4 c.391G>A (p.A131T) was the only variant 
shared by all affected family members and absent in all unaffected relatives, including in the 
extended family (Figure 4.1A). CSPG4 c.391G>A (p.A131T) is present in the ExAC browser 
(Total [forward strand]: T=6/C=118,148 alleles [MAF 5.08 x 10-5], European (Non-Finnish): 
T=5/C=64,215 alleles [MAF 7.79 x 10-5])194 but absent from the Swedish Schizophrenia 
Exome Sequencing Study (2536 cases, 2543 controls)178, 1000 Genomes196 and GoNL197.
Additional genotyping of CSPG4 discovery family variant
In an effort to further characterize the frequency of CSPG4 c.391G>A (p.A131T) in the 
Netherlands, we performed TaqMan genotyping and Sanger sequencing validation in an 
independent Dutch cohort of 1219 schizophrenia cases and in the general population-
based Rotterdam Study cohort198 (10,611 subjects). One carrier was identified among 
the schizophrenia cases (MAFcases 4.1 x 10-4) and three within the general population 
(MAFpopulation 1.4 x 10-4). The patient carrier had a long history of severe psychiatric illness 
including multiple hospital admissions and chronic anti-psychotic and anti-depressant 
medication. Her most recent prescriptions included penfluridol oral depot (20 mg/week) 
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Figure 4.1 Familial segregation of CSPG4 mutations with schizophrenia. (A) Pedigree of multiplex 
discovery family with schizophrenia. Symbols: filled, schizophrenia; open, unaffected; G/A, 
heterozygous carrier of the CSPG4 c.391G>A mutation (CSPG4A131T); G/G, homozygous reference. 
(B) Representative sequencing results for heterozygous carriers of the CSPG4 c.391G>A mutation. 
The lower panel reflects homozygous reference sequence. (C) Homology model of the first Laminin G 
domain of CSPG4. Structural alignment of the reference (green) and mutant model (magenta) reveals 
a difference in the predicted interaction between amino acid positions 131 and 96 (Leu) in the opposing 
.-strand inside the hydrophobic core of the .-sandwich (predicted alterations of the side-chains in 
red). (D) Family pedigrees segregating the CSPG4 c.2702T>G mutation (CSPG4V901G). Symbols: 
filled, schizophrenia; open, unaffected; T/G, heterozygous carrier of the CSPG4 c.2702T>G mutation; 
T/T, homozygous reference. (E) Three-dimensional structural homology modeling of the putative 3rd 
LamG domain of CSPG4 (a.a. 634-921), demonstrating the outside surface location of Val901. (F) 
Representative Sanger sequencing trace of heterozygous carrier of the CSPG4 c.2702T>G mutation.
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and venlafaxine (37.5 mg/day). Family members could not be ascertained for additional 
psychiatric history or genotyping. Among the three unrelated carriers (maximum pairwise 
    = 0.078) identified in the Rotterdam Study general population cohort, two had a clinically 
significant history of psychiatric illness (  = 0.055). One of the subjects had a history of 
multiple inpatient psychiatric hospitalizations for depression, and the other required chronic 
antidepressant and anxiolytic pharmacotherapy. Notably these findings were unlikely due to 
chance alone, given the 12.76% period prevalence of antidepressant use in the Rotterdam 
Study cohort and 0.065% annual prevalence of inpatient psychiatric hospitalization in the 
Netherlands199,200 (Binomial P = 8.8 x 10-3).
Identification of a second rare CSPG4 variant that segregates with schizophrenia
A previous study identified suggestive linkage at chromosome 15q22-24, containing 
CSPG4, in a cohort of 175 families with schizophrenia or schizoaffective disorder of 
Central American/Hispanic origin201,202. We therefore sequenced the full open reading 
frame of CSPG4 in one proband from each of the 73 families that positively contributed to 
the linkage signal at this locus (markers D15S131 and D15S655) (Supplementary Table 
4.4). Four rare missense variants were identified with MAF < 0.005 (ExAC Browser Latino) 
(Figure 4.1, Supplementary Figure 4.1). However in contrast to the other three variants, 
CSPG4 c.2702T>G (p.V901G) was found in two independent families, without evidence 
of incomplete penetrance (Figure 4.1D, F), and located within a LamG domain similar to 
the c.391G>A (p.A131T) discovery family variant (Figure 4.1). Moreover, the c.2702T>G 
p.V901G variant was nominally enriched in cases from the Swedish Schizophrenia Exome 
Sequencing Study178 (MAFcases 2.19 x 10-3; MAFcontrols 5.82 x 10-4, Fisher’s Exact Test P = 
0.026, OR 3.77, 95% CI 1.05-13.52). Together, these findings suggest that rare coding 
variants of CSPG4 might influence the risk of familial schizophrenia.
Structural protein modeling of CSPG4 mutations
The CSPG4A131T and CSPG4V901G mutations are located within the first and third Laminin G 
domain of the protein encoded by CSPG4, known as neural/glial 2 (NG2) (Figure 4.1C, E). 
Laminin G (LamG) domains are highly conserved across a diverse group of extracellular 
matrix proteins203. Intriguingly, several schizophrenia-associated genes such as NRXN1 
and LAMA2 also contain LamG domains180,204–206. Crystal structures of LamG domains in 
the Protein Data Bank allowed homology modeling of the LamG domains of NG2. Models 
implemented using Phyre2207 and I-TASSER208 both suggested that in the reference 
sequence, Ala131 and Leu96 interact across opposing b-sheets inside the hydrophobic core 
of the b-sandwich. The mutation of Ala131, which has a small hydrophobic side chain, to 
Thr131, containing a larger polar side-chain, suggests a conformational change impairing the 
proper folding of the b-sandwich (Figure 4.1C).
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Interestingly, CSPG4V901G is located in a putative 3rd LamG domain predicted by I-TASSER208 
(a.a. 634-921, Figure 4.1E). This region has not previously been annotated as a LamG 
domain, despite the striking structural homology to other LamG domains with available 
crystal structures, most notably that of NRXN1209–211. In contrast to the CSPG4A131T mutation 
that is located on the inside of the globular structure of the first LamG domain of NG2, the 
CSPG4V901G mutation is predicted to be located on the outside of the putative third LamG 
domain (Figure 4.1E), therefore perhaps affecting protein-protein interactions. Intriguingly, 
the same protein region has been found to bind to collagen V and VI, implicated in cell 
adhesion and migration of NG2-expressing cells212,213.
Family-based iPSC modeling of the CSPG4A131T mutation
No evidence for a cell-autonomous neuronal phenotype
Recent genetic and iPSC-based studies of schizophrenia have converged on a model by 
which neuronal function, and in particular synaptic transmission, is a major pathophysiological 
mechanism34,173,178,181,182. We obtained skin biopsies for iPSC reprogramming from three 
affected CSPG4A131T carriers and three unaffected non-carriers within the core sibship of 
the discovery family (Supplementary Figure 4.2 A-D). Directed differentiation of iPSCs 
yielded forebrain-specified neural progenitor cells (NPCs) uniformly positive for Nestin, 
SOX2, Vimentin, and FOXG1 (Supplementary Figure 4.2E).
NPCs were differentiated to neural cultures for 8-10 weeks, which notably lack cells of 
the oligodendrocyte lineage including OPCs. Both control and patient-derived neurons 
developed robust synaptic network connectivity, confirmed by confocal immunofluorescence 
(Figure 4.2, A-C) and whole-cell patch-clamp electrophysiological recordings (Figure 4.2, 
D-R). Overall, neurons derived from patient carriers and their unaffected siblings had similar 
electrophysiological properties, including passive membrane properties, action potential 
characteristics, and synaptic physiology. Of the twelve different electrophysiological 
parameters examined, input resistance (t50=2.54, P=0.01) and action potential threshold 
(t49=2.84, P=0.007) exhibited nominally significant differences that did not survive Bonferroni 
correction. Accordingly, the lack of a robust neuronal phenotype is consistent with the 
absence of expression of NG2 in neurons214.
Abnormal posttranslational processing and 
subcellular localization of CSPG4A131T in OPCs
Given the highly abundant expression of NG2 in OPCs, widely referred to as NG2 cells, we 
next sought to investigate the influence of the CSPG4A131T mutation on iPSC-derived OPCs. 
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Directed differentiation of iPSCs to OPCs resulted in robust expression of the lineage 
specific markers NG2, PDGFRα, Olig2, and SOX10 (Supplementary Figure 4.3). We first 
examined the subcellular distribution of NG2, as the structural homology modeling of the 
CSPG4A131T mutation suggested aberrant protein folding (Figure 4.1C). Since NG2 is a 
transmembrane protein, it requires processing by the secretory pathway. Consistent with 
an impairment of protein processing, CSPG4A131T patient-derived OPCs showed a highly 
abnormal subcellular localization of NG2 exemplified by an increase of co-localization with 
the endoplasmic reticulum marker calreticulin (t=5.08, P = 0.007) (Figure 4.3A, B).
In order to further characterize the alteration of NG2 subcellular localization, we performed 
surface biotinylation of CSPG4A131T patient and non-carrier sibling control OPCs. NG2 is 
known to undergo extensive posttranslational modification215,216, including the addition of 
chondroitin sulfate moieties at Ser999217. Consequently, NG2 appears as multiple bands 
by western blotting: a sharp band at 300 kDa corresponding to an unmodified form 
of NG2 which lacks chondroitin sulfate side chains, and a large polydisperse smear at 
>300 kDa corresponding to NG2 with chondroitin sulfate modification. Pre-incubation with 
chondroitinase ABC to enzymatically cleave the chondroitin sulfate side chains eliminated 
the >300 kDa polydisperse smear (modified NG2) and increased the 300 kDa band 
(unmodified NG2) (Supplementary Figure 4.4A).
The total level of NG2 protein was similar between patient and control OPCs in whole 
cell lysates (t=0.51, P = 0.62) (Supplementary Figure 4.4, 4.5). However, patient OPCs 
exhibited a significant decrease in the ratio of modified versus unmodified NG2 compared 
to control OPCs. This finding was observed in whole cell lysate (t=2.88, P=0.04), as well 
as independently in the intracellular (t=3.50, P=0.02) and surface protein fractions of 
OPCs (t=3.31, P=0.03) (Supplementary Figure 4.4B, C). Taken together, these results 
demonstrate that the CSPG4A131T mutation results in abnormal processing of NG2 protein.
Abnormal morphology of OPCs derived from CSPG4A131T mutation carriers
In addition to the abnormal processing of NG2 protein, we also observed distinct 
morphological differences between OPCs derived from patients and controls (Figure 4.3C). 
Patient-derived OPCs exhibited a size distribution that was strongly shifted towards smaller 
cells, a finding that was highly significant across all patient and control lines (Kolmogorov-
Smirnov D=0.25, P=3.0 x 10-8; Figure 4.3D). Overall, these results suggest that abnormal 
processing of NG2 influences the function of OPCs derived from CSPG4A131T mutation 
carriers.
Patient OPCs have reduced viability and oligodendrogenesis
Abnormally high co-localization of mutant NG2 with calreticulin is consistent with retention of 
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 Figure 4.2 Normal passive, active, and synaptic function in CSPG4A131T patient iPSC-derived 
neurons. (A) Immunostaining of iPSC-derived neural cultures after 8 weeks of differentiation (scale bar 
= 10 µm). (B, C) Immunostaining with MAP2, PSD95 and synapsin antibodies confirmed the presence 
of synaptic proteins on dendrites of iPSC-derived neurons 8 weeks post-differentiation (scale bar = 2 
µm).  (D-R) Electrophysiological measurements of iPSC-derived neurons. (D) Representative voltage 
responses to hyperpolarizing (-20 – 0 pA, 5 pA increments) and depolarizing (10 and 20 pA) current 
steps (left: control, right: patient). (E) Resting membrane potential (RMP) (t44=1.04, P=0.30). (F) Input 
resistance (t50=2.54, P=0.01). (G) Current-voltage (I-V) relationship of patient and control cells. 
(H) AHP peak (t49=1.35, P=0.18). (I) Representative traces of spontaneous action potential (AP) firing 
(50 sec at RMP; top: control, bottom: patient). (J) AP amplitude (t49=0.31, P=0.76). (K) Spontaneous 
firing rate (t19=0.03, P=0.98). (l) AP half width (t49=0.65, P=0.52). (M) AP voltage threshold 
(t49=2.84, P=0.007). (n) Representative traces of spontaneous postsynaptic currents (100 sec at 
-90 mV; top: control, bottom: patient). (O) sPSC amplitude (t17=1.94, P=0.07). (P) sPSC frequency 
(t17=0.65, P=0.52). (Q) sPSC rise time (t17=0.84, P=0.41). (R) sPSC decay time (t17=0.84, P=0.41). (D-
R), Unpaired two-tailed Student’s t-test. Passive properties and evoked APs (N=24 control, N=28 
patient). Spontaneous APs (N=11 control, N=9 patient). Spontaneous postsynaptic currents (N=12 
control, N=7 patient).  All error bars are +/- standard errors of the mean (SEM).
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impairments of cell viability resulting from misfolded proteins218,219 led us to hypothesize that 
the abnormal subcellular distribution of mutant NG2 might reduce the viability of OPCs. 
Therefore, we performed a longitudinal monitoring of cell viability using a quantitative 
fluorescence-based indicator based on the conversion of non-fluorescent resazurin to its 
fluorescent metabolite resorufin220. As evident throughout the entire 13-day time course 
of monitoring, OPCs derived from CSPG4A131T mutation carriers exhibited a significant 
decrease of cell viability (two-way repeated measures ANOVA, P = 8.9 × 10−7; Figure 4.3E).
OPCs are the exclusive precursor of oligodendrocytes221. Given the reduced viability of 
patient OPCs, we also investigated whether their maturation to oligodendrocytes might 
also be impacted. Therefore, we performed ex vivo co-culture of control and patient OPCs 
with organotypic slices of cerebral cortex from myelin-deficient Shiverer mice that carry a 
homozygous mutation of Mbp. The Shiverer myelination assay is a widely implemented 
method for assessing the myelination potential of OPCs, using culture conditions that 
promote OPCs differentiation to myelinating oligodendrocytes222. Consequently, MBP 
expression is entirely attributable to cells differentiated from the transplanted human 
OPCs, since Shiverer mice themselves lack Mbp. Consistent with their decreased viability, 
patient OPCs exhibited an impaired maturation to MBP-expressing oligodendrocytes 
(t = 2.17, P = 0.038; Figure 4.3F, G). 
 Figure 4.3 Aberrant NG2 subcellular localization, morphology, and viability of CSPG4A131T patient 
OPCs. (A, B) Immunostaining for NG2 and calreticulin (CALR) reveals increased ER colocalization 
of NG2 in patient OPCs (scale bar = 10 µm). Quantification was performed in two independent 
experiments with three control and three patient OPC lines each (t = 5.08, P = 0.007). (C) OPCs derived 
from mutation carriers exhibit an abnormally small morphology (scale bars = 10 µm). (D) Cumulative 
distribution of OPC area (µm2; n = 361 control cells, n = 217 patient cells) demonstrates that OPCs 
derived from affected mutation carriers are significantly smaller than from their unaffected non-carrier 
siblings. Control and patient cell size distributions were compared by Kolmogorov–Smirnov test 
(D = 0.25, P = 3.0 × 10−8). Dark lines show group mean ± standard error. Gray and pink lines show the 
results from each of the individual control and patient subjects, respectively. (E) Fluorometric cell viability 
assay of OPCs derived from affected mutation carriers vs. their unaffected non-carrier siblings (two-
way repeated measures ANOVA, P = 8.9 × 10−7). (F) Representative z-stacked images of organotypic 
cerebral cortex slices of homozygous shiverer mice transplanted with OPCs derived from affected 
mutation carriers or their unaffected non-carrier siblings. Human nuclear antigen (hNA), green; MBP, 
red (scale bar = 100 µm). (G) MBP surface area normalized to hNA+ cells per slice (t = 2.17, P = 0.038).
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Transfection of OPCs with mutant isoforms of NG2
To further investigate the causality of the CSPG4A131T and CSPG4V901G mutations, we 
transfected either the wild-type (WT) or mutant isoforms into OPCs derived from healthy 
non-carrier siblings. Expression of CSPG4A131T recapitulated the abnormal retention in the 
endoplasmic reticulum, similarly as observed in patient OPCs (one-way ANOVA, WT vs. 
A131T: P = 5.2 × 10−9; Figure 4.4A, B). Moreover, OPCs expressing the CSPG4V901G mutation 
also exhibited a significantly increased proportion of cells with co-localization to the 
endoplasmic reticulum compared to WT transfected OPCs (WT vs. V901G: P = 7.5 × 10−6), 
albeit lower than observed for the CSPG4A131T mutation. Notably, however, expression of 
the CSPG4V901G mutation resulted in a distinct accumulation within putative intracellular 
vesicles that was evident in both OPCs (Figure 4.4A, inset) and U373 glioblastoma cells 
(Supplementary Figure 4.6), but not observed with expression of the CSPG4A131T mutation 
in either of these cell types. At present, although we have not yet succeeded in identifying 
the subcellular compartment to which these CSPG4V901G-expressing intracellular vesicles 
belong, lysosomes have been excluded based on the lack of significant co-localization with 
lysosomal-associated membrane protein 1 (Supplementary Figure 4.6).
Lastly, we sought to evaluate the causality of CSPG4 mutations for mediating the impaired 
cell viability observed for patient OPCs. Therefore, we performed transient transfections of 
either WT or mutant NG2 isoforms into OPCs derived from healthy non-carrier siblings and 
assessed cell survival after 48 h when plasmid expression was maximal. OPCs transfected 
with either CSPG4A131T or CSPG4V901G   exhibited a significant decrease in survival compared 
to CSPG4WT (one-way ANOVA, WT vs. A131T: P = 0.006; WT vs. V901G: P = 3.4 × 10−4; 
Figure 4.4C). Notably, we also attempted the same experiment with patient OPCs; however, 
patient OPCs consistently died following the transfection procedure, regardless of whether 
the transfection was performed using WT or mutant NG2, or empty vector, a finding that 
independently confirms their distinct vulnerability.
Impaired white matter microstructure in CSPG4A131T mutation carriers
Given the observed abnormalities of patient-derived OPCs, we reasoned that affected 
CSPG4A131T mutation carriers might exhibit impairments of white matter integrity since OPCs 
are the exclusive precursor of myelinating oligodendrocytes. Therefore, we performed 
brain magnetic resonance imaging (MRI)-based diffusion tensor imaging (DTI) in affected 
carrier and unaffected non-carrier siblings and compared them with 294 subjects from the 
general population Rotterdam Study cohort matched for age, gender, smoking behavior, 
and alcohol use (Figure 4.5A). DTI images were analysed for global and focal reductions 
in fractional anisotropy (FA), the latter referred to as white matter potholes223. Consistent 
with the hypothesis that the CSPG4A131T mutation compromises the integrity of myelination, 
affected carriers exhibited both a significantly higher number of white matter potholes (P = 
2.2 x 10-5) and lower global FA (P = 8.2 x 10-3), compared to unaffected sibling and matched 
general population controls (Figure 4.5B, C).
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Figure 4.4 Transfection of CSPG4A131T and CSPG4V901G mutations in healthy non-carrier sibling OPCs. 
Control OPCs were transiently transfected with plasmids expressing WT or mutant CSPG4 isoforms 
fused to EGFP. (A) Confocal images of transfected cells confirm a normal extracellular membrane-
localization of CSPG4WT-EGFP. In contrast, a high proportion of OPCs transfected with CSPG4A131T-EGFP 
exhibited colocalization with the endoplasmic reticulum marker calreticulin (CALR), reminiscent to patient 
OPCs with endogenous CSPG4A131. OPCs expressing CSPG4V901G-EGFP also revealed an increased 
proportion with CALR colocalization, but additionally demonstrated a distinctly abnormal targeting within 
putative intracellular vesicles that were negative for CALR (insets) (scale bars: main panels = 10 μm, 
insets = 3 μm). (B) Percentage of transfected OPCs with colocalization of CSPG4 isoforms with CALR 
(WT vs. A131T: t = 10.36, P = 5.2 × 10−9; WT vs. V901G: t = 6.20, P = 7.5 × 10−6). (C) Cell survival at 48 h after 
transfection of OPCs (WT vs. A131T: t = 3.11, P = 0.006; WT vs. V901G: t = 4.41, P = 3.4 × 10−4).
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Figure 4.5 White matter abnormalities in CSPG4A131T patients. (A) White matter potholes found in the two 
affected family members are shown in red and blue, respectively. Purple regions define a spatial overlap of 
potholes in both patients. The z-measures provide coordinates of the axial plane in MNI-space. (B) Mean 
number of potholes comparing the matched control population to the unaffected and two affected family 
members. (C) Whole-brain white matter fractional anisotropy (FA) comparing the matched general population 
subjects to unaffected and affected family members. Error bars in B and C reflect the standard deviation of the 
matched general population subjects. The number above each bar reflects the individual z-score compared to 
the matched general population group.
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Discussion
Our findings provide convergent genetic and functional neurobiological evidence that 
oligodendrocyte progenitor cell dysfunction might influence the pathophysiology of 
schizophrenia. We identified two different rare missense mutations in CSPG4 exhibiting 
familial segregation with schizophrenia. The discovery family CSPG4A131T mutation was 
associated with abnormal protein processing, OPC morphology, cellular viability, and 
oligodendrogenesis. The second mutation (CSPG4V901G), also located in a LamG domain, 
segregated with schizophrenia in two independent pedigrees and exhibited nominally 
significant enrichment in the Swedish Schizophrenia Exome Sequencing Study178. 
Moreover, induced expression of CSPG4A131T and CSPG4V901G isoforms confirmed the 
likely pathogenicity of these mutations for OPC function. Importantly, however, our findings 
leave still unaddressed the question of the extent to which there are distinct vs. shared 
pathophysiological mechanisms in schizophrenia attributable to common polygenic risk, 
CNVs or other familial variants. 
Our genetic findings highlight some of the challenges frequently encountered in the effort 
to identify pathogenic rare variants underlying common diseases such as schizophrenia. 
Although we identified three independent families exhibiting segregation of two different 
rare CSPG4 missense variants with complete penetrance, none of these families was large 
enough on its own to achieve a genome-wide significant LOD score. Moreover, although 
the rare MAF of the CSPG4A131T mutation precluded case/control validation in the Swedish 
Schizophrenia Exome Sequencing Study, two of the three CSPG4A131T mutation carriers 
in the general population Rotterdam Study cohort had a clinically significant history of 
psychiatric illness that was unlikely due to chance. Furthermore, the CSPG4V901G mutation 
was present in the Swedish cohort with a nominally significant enrichment in cases versus 
controls. Additional follow-up studies in larger cohorts will be required to definitively evaluate 
the association between schizophrenia and rare CSPG4 variants.
Genetic variation in CSPG4 might confer a pleiotropic risk for mental illness since two 
of the CSPG4A131T mutation carriers identified in the general population Rotterdam Study 
cohort had a clinically significant history of depression. Interestingly, a mouse model of 
OPC depletion was recently shown to exhibit depression-like behavior224. Such pleiotropic 
influences on mental health outcomes would be consistent with many of the previously 
identified genetic risk factors for schizophrenia225,226. Furthermore, originally named as 
melanoma-associated chondroitin sulfate proteoglycan upon its cloning227, NG2/CSPG4 
has since been widely implicated in a wide variety of human cancers both as a diagnostic 
marker and a therapeutic target, including for glioblastoma and melanoma228,229.
The protein sequence surrounding the CSPG4A131T mutation is conserved only among 
higher-order primates, suggesting recent evolutionary pressure. In contrast, the CSPG4V901G 
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variant is predicted to be a disease-causing mutation by PolyPhen2230. In non-primate 
vertebrates, the reference amino acid at position 131 is threonine, corresponding to the 
patient mutation CSPG4A131T and contributing to a benign PolyPhen score. Interestingly, this 
is analogous to the human SNCAA53T mutation, one of the most well established mutations 
for autosomal dominant Parkinson’s Disease231. In mice, the reference amino acid at SCNA 
position 53 is a threonine. But notably, although transgenic expression in mice of the 
reference human SCNA sequence is benign, introduction of the human SNCAA53T mutation 
is highly pathogenic231.
To investigate the cellular pathophysiology resulting from mutation of CSPG4, we derived 
iPSCs from affected and unaffected siblings of the discovery family. Detailed 
electrophysiological analysis of patient-derived neurons revealed an increase in 
input resistance and depolarized shift in AP threshold. Multiple previous studies have 
demonstrated primary functional neuronal mechanisms in human iPSC models of 
schizophrenia34,173,178,181,182,232; however, the changes we observed are distinct from those 
previously identified. Therefore, future studies will be required to determine the extent to 
which these differences may have pathophysiological relevance, and potentially reflect an 
increased burden of common polygenic risk as recently observed in familial schizophrenia233. 
Importantly, however, our limited findings in neurons compared to OPCs cannot be considered 
to imply that neuronal dysfunction is not central to the pathophysiology of schizophrenia. 
Rather, these data suggest that although the symptoms of schizophrenia are ultimately 
manifest from neuronal dysfunction, the primary pathophysiological mechanism could be 
mediated by direct neuronal impairments and/or indirectly through non-neuronal cell types 
including OPCs, depending upon the nature of the etiological factors driving disease risk in 
a given individual.
OPCs receive extensive GABAergic input from surrounding neurons, which regulate their 
differentiation to myelinating oligodendrocytes234–237. However, it has remained less well 
understood whether OPCs directly modulate neuronal function independent of myelination. 
Notably, two recent studies have suggested novel candidate mechanisms by which OPC 
dysfunction might directly regulate neuronal function, including activity-dependent ecto-
domain cleavage of NG2216 and local buffering of extracellular potassium238.
Regarding the identified CSPG4 mutations demonstrating familial segregation with 
schizophrenia, alterations in myelination are a parsimonious candidate mechanism 
given the convergent findings of genetic mutations in the OPC marker protein CSPG4, 
functional impairments of iPSC-derived OPCs, and in vivo DTI-based structural brain 
imaging. Moreover, the abnormal subcellular localization of NG2 in OPCs expressing the 
CSPG4A131T or CSPG4V901G isoforms is consistent with the high susceptibility of cells of the 
oligodendrocyte lineage to disruptions in the secretory pathway, as their maturation requires 
a substantial upregulation of membrane protein expression239.  Interestingly, earlier work 
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has shown a precedent for altered subcellular localization of NG2, in which mutation of 
Ser999 results in an abrogation of chondroitin sulfate side chain modification and altered 
subcellular localization217.
Taken together, these findings are highly consistent with the growing body of evidence 
implicating white matter integrity in schizophrenia neuropathology223,240–242. Indeed, recent 
findings demonstrating myelination of parvalbumin-positive GABAergic interneurons – 
arguably the most well established neuronal cell type implicated in the pathophysiology of 
schizophrenia243,244 – raises the intriguing possibility that schizophrenia might result from 
neurodevelopmental alterations of PV interneuron myelination245.
In summary, our findings support the validity of family-based genetics and iPSC modeling 
to unravel the underlying mechanisms of complex, heterogeneous psychiatric diseases, 
and provide evidence in support of oligodendrocyte precursor cell dysfunction as a novel 




Recruitment of family with schizophrenia and obtaining patient material
A Dutch white Caucasian non-consanguineous family with a high incidence of schizophrenia 
was ascertained. Written informed consent was obtained from all participating subjects. 
This study was approved by the medical ethical committee of the Erasmus University 
Medical Centre (Rotterdam, The Netherlands). Participating family members were 
screened for current or past psychiatric symptoms using the Structural Clinical Interview 
for DSM-IV (SCID-1)246. Medical screening revealed no evidence of somatic comorbidities, 
dysmorphologies, or neurological symptoms. All individuals with schizophrenia were 
documented to be of average intelligence at the time of their initial diagnosis. DNA isolation 
from venous blood samples and skin biopsies were performed using standard procedures. 
Two family members (II-2 and III-9) passed away since the start of the study.
For skin biopsies, a small area of skin of the medial aspect of the upper arm was anesthetized 
with an EMLA patch (AstraZeneca) for one hour, after which the skin was disinfected with 
ethanol and the biopsy was obtained through all skin layers with a standard 3mm biopsy 
punch. The tissue was collected in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco-
Invitrogen) without additives and transferred to culture within 24 hours. Primary human 
fibroblasts were cultured in DMEM containing 10% fetal calf serum and 1% penicillin/
streptomycin (P/S).  
Genetic analysis
Genomic DNA was isolated using standard methodology from 14 family members, including 
13 by whole blood samples and one subject (pedigree ID II-1) using paraffin-embedded 
tissue (Figure 4.1A). Linkage and Copy Number Analysis was performed with Illumina 
HumanCytoSNP-12v2 chip arrays (294,975 markers). Linkage analysis was conducted 
exclusively for the purpose of identifying a genome-wide set of candidate chromosomal 
regions shared by all affected family members (defined as those regions with a LOD score > 
0). Linkage was performed using Allegro and implemented in the EasyLinkage version 5.08 
interface247 with one marker every 0.5 cM using a co-dominant allele frequency algorithm 
and dominant scoring function. Unaffected family members were considered as having an 
unknown affection status in the linkage model, providing no a priori constraints on the rate 
of incomplete penetrance. Copy number analysis was performed using NEXUS discovery 
edition, version 6 (BioDiscovery, El Segundo, CA), which did not indicate the presence of 
copy number variants segregating with the phenotype. The strongest evidence of linkage 
was observed on chromosomes 2, 11, 14, 15, and 16, involving a total of 294.34 Mb of 
genomic loci.
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Whole exome sequencing was performed on three individuals of the discovery family 
(pedigree IDs: II-2, III-5 and III-9). Sequencing was performed twice for all three samples: 
initially at 40x, and subsequently at 90x coverage. Exome sequencing was performed using 
in-solution capturing (Agilent SureSelect V2 and V4 Human 50 Mb kit respectively, Agilent 
Technologies) and paired-end sequencing with Illumina Hi-Seq 2000 sequencers. Reads 
were aligned to the human reference genome version 19 using Burrows-Wheeler Aligner. 
SNPs and indels were called using the Genome Analysis Toolkit (GATK). 
The heterozygous variants were filtered based on the following criteria: a) present within 
the candidate genomic regions shared among all affected family members, b) predicted 
to affect protein coding (missense, nonsense, frameshift, splice site), c) called in at least 
one of the affected individuals [III-5 and III-9], d) absent from the unaffected mother [II-2], 
e) absent from dbSNP129, and f) with a minor allele frequency (MAF) of < 0.001 in in the 
Exome Aggregation Consortium (ExAc) browser (European non-Finnish)194, Exome Variant 
Server (EVS6500, NHLBI Exome Sequencing Project)195, 1000 Genomes196, and Genome 
of the Netherlands197 cohorts.
Genotyping of CSPG4 c.391G>A was performed in a cohort of Dutch subjects with 1219 
schizophrenia cases and 10,611 controls. Genotyping of 763 schizophrenia cases and 
386 healthy control subjects were performed using a custom Illumina Infinum Human 
Exome Beadchip array (Genetic Risk and Outcome of Psychosis [GROUP] / Utrecht 
cohort study248). TaqMan genotyping was performed on an additional 456 locally-collected 
schizophrenia cases and 10,225 population-based controls filtered for identity by descent 
(  < 0.25) (Rotterdam Study198). All samples with ALT calls by exome array or TaqMan 
genotyping were validated by Sanger sequencing, particularly given the existence of the 
CSPG4P13 pseudogene with high homology to the region surrounding CSPG4 c.391G>A 
(Supplementary Figure 4.7).
Taqman genotyping of CSPG4 c.391G>A was performed with the following primers and 
probes: F_GGCTGGTTCCCCTCAGGTA, R_GTGGTGCTGACTGTCGTAGAG,
VIC_TTTCTGAACGCCTCCTC, FAM_TTTCTGAACACCTCCTC. The following primer sets 
were used for Sanger sequencing of CSPG4 c.391G>A: F_TCTGGGGCCCCAAGTGTGG 
and R_AGAGTGGGGCCCAGAGAAGC, with an internal forward primer for sequencing: 
Fseq_GGGCCAGGAGGAGCTGAGG. A second primer set was used for confirmation: F2_
CCACTCCCCATCTCTCTTCAGG and R2_CAGGGCCACATCATCACTGG. CSPG4P13 





Homology modeling of the first Laminin G domain (amino acids 29-176) was performed 
independently using both the Protein Homology/analogY Recognition Engine – Version 2.0 
(Phyre2)207 and Iterative Threading ASSEmbly Refinement (I-TASSER)208 protein structure 
prediction servers. All 148 residues (100%) of the reference and mutant sequences 
were modeled at >99% confidence by Phyre2 using intensive mode. For I-TASSER, the 
confidence (C-score) was 0.81 and topological similarity (TM-score) was 0.82+/- 0.08, for 
both models. Reference and mutant models were structurally aligned with PyMol (http://
www.pymol.org).
Generation and characterization of iPSCs
Reprogramming of human primary skin fibroblasts was performed as previously described249. 
Briefly, fibroblasts were infected with a multicistronic SIN lentiviral vector containing an SFFV 
promoter, encoding OCT4, SOX2, KLF4 and MYC, as well as dTomato to visualize reprogramming. 
Emerging iPSC colonies were cultured on γ-irradiated mouse embryonic fibroblasts. All iPSC 
lines and their derivatives used in this study were screened monthly for mycoplasma. 
Characterization of iPSC clones was performed by RT-PCR (Supplementary Figure 4.2A), 
immunostaining for un-differentiated human ES markers (Supplementary Figure 4.2B) and 
markers of three embryonal germ layers on embryoid bodies (EBs) differentiated in vitro 
(Supplementary Figure 4.2C). Total RNA of iPSCs was isolated for RT-PCR using standard 
protocols (primers listed in Supplementary Table 4.5). For EB differentiation, iPSC colonies 
were dissociated by collagenase IV treatment and transferred to ultra-low attachment 6-well 
plates (Corning). Floating EBs were cultured in iPSC medium without bFGF for a minimum 
of 6 days with supplemented SB431542 (Tocris Bioscience) for ectoderm conditions only. 
EBs designated for endoderm differentiation were transferred to gelatin-coated 12-well 
plates containing the following medium: RPMI 1640 (Gibco-Invitrogen), supplemented with 
20% FBS, 1% P/S, 1% glutamine and 0.4mM alpha-thioglycerol. Mesoderm differentiation 
from the EBs was induced in gelatin-coated 12-well-plates with DMEM medium (low 
glucose) supplemented with 15% fetal bovine serum, 1% P/S, 1% glutamine and 1% MEM-
non-essential amino acids. Ectoderm differentiation was induced in Matrigel (BD)-coated 
plates with the following medium: neurobasal medium (Gibco-Invitrogen) and DMEM/F12 
(v/v 50/50) supplemented with 1% P/S, 1% glutamine, 1% MEM-non-essential amino acids, 
0.02% BSA (Gibco-Invitrogen), 0,5% N2 (Gibco-Invitrogen) and 1% B27 (Gibco-Invitrogen). 
After two weeks in culture, cells were fixed with 4% formalin for immunolabeling.
IPSCs were cultured in standard human embryonic stem (hES) cell culture medium containing 
DMEM/F12 (Gibco-Invitrogen) supplemented with 20% knock-out serum replacement 
(Gibco-Invitrogen), 2mM L-glutamine (Gibco-Invitrogen), 1% P/S (Gibco-Invitrogen), 1% 
MEM-non-essential amino acids (PAA Laboratories GmbH), 0.1mM β-mercapto-ethanol, 
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and 10 ng/ml bFGF (Gibco-Invitrogen).  Medium was replenished daily and colonies were 
passaged weekly using collagenase IV (1 mg/ml, Gibco-Invitrogen) with 10µM ROCK 
inhibitor (Y-27632, Sigma).
Karyotype analysis
iPSCs were dissociated to single-cell suspension using TrypLE Express (Gibco-Invitrogen) 
and plated feeder-free in mTeSR1 medium on three Matrigel-coated wells of a 6-well plate 
in the presence of 10µM ROCK inhibitor. The next day, cells were harvested using TrypLE 
Express, treated with colcemid (200 ng/ml) and hypotonic solution, and fixed using Carnoy’s 
Fixative. At least 20 metaphases were analysed for each clone, for which the chromosome 
count was considered normal if more than 70% of cells analysed had 46 chromosomes. 
More detailed karyotypic analysis with RBA and QFQ band analysis was performed for 
one individual patient clone (individual III-11) to further exclude segregating cytogenetic 
abnormalities (Supplementary Figure 4.2D).
Neuronal differentiation 
iPSC colonies were dissociated from MEFs with collagenase IV and transferred to non-
adherent plates in hES cell medium on a shaker in an incubator at 37ºC/5% CO2. After 
two days, EBs were changed to neural induction medium [DMEM/F12, 1% N2-supplement 
(Gibco-Invitrogen), 2 µg/ml heparin (Sigma), 1% P/S] and cultured for another four days in 
suspension. EBs were gently dissociated and plated onto laminin-coated dishes in neural 
induction medium. Cells were dissociated with collagenase IV after 8 days and plated onto 
laminin-coated dishes in NPC medium [DMEM/F12, 1% N2, 2% B27-RA, 1 µg/ml laminin 
(Sigma) and 20 ng/ml FGF2 (Millipore), 1% P/S]. After one week, NPCs were dissociated 
with collagenase IV, re-plated, and passaged 1:4 weekly. For neural differentiation, 
passage 5 NPCs were plated on coverslips coated with 100 µg/ml poly-L-ornithine (Sigma) 
and 50 µg/ml laminin in neural differentiation medium consisting of Neurobasal medium 
supplemented with 1% MEM-non-essential amino acids, 1% N2 supplement, 2% B27-RA 
supplement, 20 ng/ml BDNF (ProSpecBio), 20 ng/ml GDNF (ProSpecBio), 1 mM db-cAMP 
(Gibco-Invitrogen), 200 mM ascorbic acid (Gibco-Invitrogen), 2 μg/ml laminin and 1% P/S. 
Electrophysiological recordings 
After 8-10 weeks of neuronal differentiation, culture slides were transferred to the recording 
chamber following a thirty-minute serial partial exchange of cell culture medium with artificial 
cerebrospinal fluid (ACSF) containing the following (in mM): 110 NaCl, 2.5 KCl, 2 CaCl2, 
2 MgCl2, 1 NaH2PO4, 25 NaHCO3, 10 glucose, 0.2 ascorbate (pH 7.4). In the recording 
chamber, slides were continuously perfused with ACSF at 1.5-2 mL/min, saturated with 95% 
O2/5% CO2 and maintained at 20-22°C.
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Whole-cell patch-clamp recordings were performed under infrared differential interference 
contrast visual guidance using an upright microscope (Zeiss) with borosilicate glass 
recording micropipettes (3-6 MΩ) filled with the following medium (in mM): 130 K-gluconate, 
11 KCl, 10 HEPES, 5 NaCl, 0.1 EGTA, 1 MgCl2, 2 Mg-ATP, 0.3 Na-GTP, 5 phosphocreatine 
(pH 7.4). Data were acquired at 10 kHz using an Axon Multiclamp 700B amplifier (Molecular 
Devices), filtered at 3 kHz, and analyzed using pClamp 10.1 (Molecular Devices). Whole-
cell capacitance and series resistance were compensated, and voltage was adjusted for 
liquid junction potential.
Current-clamp recordings were performed at a holding potential of -60 mV. Passive 
membrane properties were analysed using a series of hyperpolarizing and depolarizing 
square wave currents (500 msec duration, 1 sec interstimulus interval) in 5 pA steps, ranging 
from -20 to +30  pA. AP amplitude, rise time, decay time and half width were measured for 
the first evoked AP resulted by a depolarizing step, from the threshold to the peak, for which 
the threshold was defined by the moment at which the second derivative of the voltage 
exceeded the baseline. Spontaneous APs were recorded at resting membrane potential. 
Voltage-clamp recordings were performed at a holding potential of -90 mV. 
Oligodendrocyte lineage differentiation
iPSC-derived NPCs were differentiated to OPCs according to Monaco et al250, with 
modifications. NPCs were plated on laminin-coated 10 cm plates in NPC medium consisting 
of DMEM/F12, 1% N2, 2% B27-RA, 1 µg/ml laminin, 1% P/S, 25 ng/ml basic Fibroblast 
Growth Factor (bFGF) and 20 ng/ml Epidermal Growth Factor (EGF). When NPCs reached 
90% confluence, NPC medium was changed to OPC differentiation medium for three weeks: 
DMEM/HAMS F12, 1% N2, 1% BSA, 1% L-Glutamine, 1% P/S, 20 ng/ml bFGF, 10 ng/ml 
platelet derived growth factor (PDGF-AA, ProspecBio), 2ng/ml Sonic hedgehog (Shh), 2 ng/
ml neurotrophic factor 3 (NT-3) and 3 nM triiodothyronine (T3). OPC medium was changed 
every other day, and cells were passaged weekly at 1:4.
Surface Biotinylation
Biotinylation of cell surface proteins was adapted from Huang et al251, with modifications. 
First, the OPCs were washed twice in cold PBS/CaCL2/MgCl2 (2.5 mM CaCl2, 1 mM 
MgCl2, pH 7.4). Then, the OPCs were incubated for 15 minutes on ice with or without 0.3 
mg/ml of freshly dissolved Sulfo-NHS-SS-Biotin (Thermo Scientific) in PBS/CaCL2/MgCl2. 
Next, the OPCs were washed three times on ice in cold biotin quenching solution consisting 
of 50 mM glycine in PBS/CaCl2/MgCl2. Subsequently, the OPCs were lysed by incubation 
for 10 minutes on ice with lysis buffer, pH 7.4, consisting of 5 mM EDTA, 5 mM EGTA, 1% 
Phosphatase inhibitor cocktail 2 and 3 (Sigma), 1% PIC (Sigma), and 1% Triton X in PBS. 
At least 3 wells were pooled from each cell line at each experimental condition, to minimize 
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any plating or growing variability in the cell culture. A portion of the lysate was removed and 
labeled as the total fraction (whole cell lysate). The remaining lysate was then centrifuged 
(13200 rpm at 4°C for 15 minutes) to remove insoluble proteins. The supernatants were 
incubated overnight at 4°C with PBS-washed and lysis buffer-equilibrated Pierce™ 
NeutrAvidin™ Agarose beads (Life Technologies). Next, the mixture was spun down at 
2000 rpm, separating the supernatant termed the intracellular fraction from the surface 
protein fraction attached to the beads. Subsequently, the beads were washed four times by 
rotating with lysis buffer and after the final wash the beads were dried completely and taken 
up in 20 µl of lysis buffer, labeled as the surface fraction.
Sodium dodecyl sulfate (SDS)-PAGE and Western Blotting
First, 25% XT Sample Buffer (Biorad) and 10% 100mM dithiothreitol (DTT) were added 
to equal volumes of cell extract followed by heating to 65°C for 15 minutes. Then, the 
samples were electrophoresed through 4%-12% Criterion™ XT Bis-Tris gradient gels 
(Biorad) in XT-Mops buffer (Biorad). Proteins were transferred overnight at 4°C on 0.45 
µm pore nitrocellulose membrane (Biorad) in a Tris-Glycine buffer consisting of 10% Tris/
Glycine buffer (Biorad) and 20% anhydrous methanol in distilled water. Membranes were 
blocked for 2 hours while shaking at room temperature in TBST buffer containing 4% 
blotting grade blocker (Biorad). Then, the membranes were incubated with a monoclonal 
antibody generated from hybridoma B5 cells raised against purified intact NG2 protein from 
melanoma cells (generous gift from W.B. Stallcup) and mouse anti-actin (Sigma) in TBST 
buffer containing 1% Tween and 2% milk for 48 hours at 4°C followed by washing with 
TBST buffer. Finally, the blots were incubated with IRDye® secondary antibodies (LI-COR) 
against the primary antibody species for two hours at room temperature. The blots were 
washed twice in TBST and TBS followed by one wash in water, subsequently the antibody 
fluorescence was visualized using an ODYSSEY® CLx scanner (LI-COR). Quantification 
of NG2 western blot bands was performed using ImageJ software (http://imagej.nih.gov/ij/).
Shiverer co-culture assay
Experiments were approved by the Dutch Ethical Committee and in accordance with the 
Institutional Animal Care and Use Committee (IACUC) guidelines. Shiverer mice (C3Fe.
SWV-Mbpshi, Jackson Laboratory) were backcrossed >10 generations into C57BL/6J. 
Organotypic cortex slices were established from homozygous shiverer (Mbpshi/shi) mice at 
P3-P5 according to Stoppini et al252, with modifications. Briefly, the brain rapidly removed 
and transferred to ice cold Gey’s Balanced Salt Solution (Sigma) containing 5.4 mg/ml 
glucose and 1% P/S. After dividing the brain sagittally into two hemispheres, 300 m fronto-
parietal coronal slices were obtained using a tissue chopper (McIlwain). Slices were cultured 
on an air-fluid interface at 37°C with 5% CO, using culture plate inserts (Millipore: 0.4 µm 
pore size; 30 mm diameter; 3 cultures per insert) in 1.0 mL culture medium containing 
50% MEM alpha, 25% HBSS, 25% horse serum, 6.5 mg/mL glucose, 2 mM glutamine, 
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1% N2 supplement and 1% P/S, supplemented with PDGF-AA. For each Mbpshi/shi mouse, 
adjacent slices were randomly assigned for transplantation with either patient or control 
OPCs, thereby providing comparative matched pairs. Each slice was transplanted with 1 x 
104 iPSC-derived OPCs in 1.0 µL PBS containing 0.1% FastGreen (Gibco-Invitrogen) using 
a Picospritzer. OPCs were allowed to differentiate into myelinating oligodendrocytes for 10 
days, following the procedure described in Najm et al222.
Immunocytochemistry and confocal imaging
Cell cultures and organotypic slices were fixed using 4% formalin in PBS. Primary antibodies 
were incubated overnight at 4°C in labeling buffer containing 0.05 M Tris, 0.9% NaCl, 0.25% 
gelatin, and 0.5% Triton-X-100 (pH 7.4). The following primary antibodies were used: SOX2 
(AB5603), Nestin (MAB5326), MAP2 (AB5622), NeuN (MAB377), GFAP (AB5804), human 
Nuclear Antigen (hNA, MAB1281) [Millipore], FOXG1 (45-053) [ProSci], NG2-EC [kindly 
provided by W.B. Stallcup], Olig2 (AB42453), MBP (AB7349) [Abcam], Vimentin (SC6260) 
[Santa Cruz Biotechnology], AFP (MAB1368), SOX10 (AF2864) [R&D Systems], TRA-1-
81 (560072), Nanog (560482) [Beckton Dickinson], OCT4 (AB19857) [Abcam], Calreticulin 
(PA3-900) [Fisher Scientific]. The following secondary antibodies were used: Alexa-488, 
Alexa-546, Alexa-555 and Cy3 antibodies [Jackson ImmunoResearch]. Samples were 
imbedded in Mowiol 4-88 (Fluka) after which confocal imaging was performed with a Zeiss 
LSM700 confocal microscope (Apochromatic 40x objective, 1.3 NA, oil immersion) using 
ZEN software (Zeiss, Germany). 
Experimenters were blinded to group allocation when performing experiments, during data 
collection, and when assessing outcomes. OPC area (µm2) was quantified on maximum 
projection of z-stack images covering the full depth of each measured cell using a manually 
drawn surface contour in ImageJ. Quantification of human nuclei (hNA) and myelin (MBP) 
content of organotypic cortex slices was performed using Image J. Maximum intensity 
projections of tiled z-stacks covering the full dimensions of each slice with a constant 
interval of 1.0 µm were converted to individual 8-bit threshold images. Human nuclei (hNA) 
images were further segmented using a binary watershed filter. The number and surface 
area of labelled cells were quantified using the particle analysis algorithm. Cell viability 
was measured using resazurin (AlamarBlue, Thermo Fisher Scientific) in 96-well plates. 
Fluorimetric data were collected using a plate reader at a wavelength of 570 nm excitation 
and 585 nm peak emission. The data were normalised for the number of living cells using 
calcein AM (Thermo Fisher Scientific) at 488 nm excitation and 517 nm peak emission and 
quantified in adjacent wells seeded concurrently with equal numbers (2000 cells/well).
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Plasmid Transfections
Control OPCs and U373 glioma cells were transfected with cDNA constructs to express 
fusion proteins of CSPG4 and its mutant variants with C-terminal EGFP. CSPG4 cDNA 
sequence (CSPG4WT) was cloned into the Gateway vector pcDNA-DEST47 (pcDNA-
DEST47-CSPG4WT) and converted to CSPG4A131T by site-directed mutagenesis. The 
corresponding plasmid containing the CSPG4V901G sequence was obtained by sub-cloning 
a custom-ordered V901G-containing fragment (GeneArt, Thermo Fisher Scientific) into the 
pcDNA-DEST47-CSPG4WT vector. All three plasmids were confirmed by sequencing. OPCs 
were transfected with CSPG4WT-EGFP, CSPG4A131T-EGFP, or CSPG4V901G-EGFP using 
X-TremeGENE transfection reagent (Sigma-Aldrich) with 0.1 mg DNA per 96-well, or 1.0 mg 
DNA per 12-well. Cells were fixed 48 hours after transfection.
Magnetic Resonance Imaging (MRI)
Two patients and two control siblings of the discovery family provided additional written 
informed consent for MRI scanning. One of the unaffected siblings was excluded due to a 
history of systemic chemotherapy known to influence white matter integrity253. Population 
controls (n=294) were selected from the Rotterdam Study based on matching for age, 
gender, smoking behavior, and alcohol use. All subjects, including population controls and 
family members, were imaged using the identical MRI scanner and acquisition protocol.
MRI images were obtained using a 1.5 Tesla General Electric scanner (GE Healthcare, 
Milwaukee, Wisconsin, USA, software version 11X), with a bilateral phased-array head 
coil. A full description of the imaging protocol has been described previously254. Diffusion-
weighted imaging was performed using echo planar imaging (EPI) sequences collected in 
25 directions with a b value of 1,000 s/mm2 and three b = 0 images. Additional sequence 
parameters were TR = 8,000 ms, TE = 74.6 ms, bandwidth 14.71 kHz, flip angle = 13, 
acceleration of 2, and a voxel resolution of 3.3 x 2.2 x 3.5 mm3. 
Pre-processing of the diffusion-weighted images was performed using FSL255. After 
conversion from dicom to nifti format, individual images were eddy-current corrected using 
FMRIB’s eddy_correct255 followed by skull stripping using BET256. Fractional anisotropy 
(FA) images were created by fitting a tensor model to the diffusion data using FMRIB’s 
Diffusion Toolbox (FDT)255. All subjects’ FA data were then aligned into common space using 
the nonlinear registration tool FNIRT257, which employs a b-spline representation of the 
registration warp field258. Whole brain mean FA was calculated by masking each image 
using the Johns Hopkins University White Matter Atlas (JHU WMA)259 and determining the 
mean intensity of FA within the mask.
An in-house MATLAB (Mathworks, Natick, MA) algorithm was used to quantify the number 
and spatial characteristics of white matter ‘potholes’ along the major white matter tracts260. 
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The input to the algorithm was the set of FA images that had undergone non-linear 
registration into MNI space using TBSS261. No spatial filtering was applied to the images. 
The first step was to generate a voxel-by-voxel mean and standard deviation (SD) image 
of the 294 matched population controls. These group and SD images were then used to 
individually create a voxel-wide z-image for all of the subjects, including the three family 
members. This resulted in individual z-images with each voxel based on the mean and 
SD of the matched population controls. To ensure the search involved only white matter 
regions, each image was masked with the cortical areas defined by the Johns Hopkins 
University white matter atlas259. 
The individual z-FA images were then used to search for contiguous voxels of white matter 
below a threshold of z < -2223,260. Clusters were determined by thresholding each image and 
labeling contiguous voxels in three-dimensional space that fell below the defined threshold. 
Only clusters greater than 250 voxels were used in the analyses.
Statistical Analysis
Significance of observations was established for genetic case-control analyses using 
the Fisher’s exact test. Brain imaging results in family members were evaluated using 
z-scores based on the matched population control cohort distribution. For functional 
studies, statistical comparisons were performed using two-tailed t-test, analysis of variance 
(ANOVA), or Kolmogorov-Smirnov test, as indicated. Data are expressed as mean ± S.E.M., 
unless otherwise specified. The threshold for significance was set at P<0.05 for all statistical 
comparisons.
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Supplementary Figure 4.1 Additional rare coding variants in CSPG4. (A) Pedigrees with CSPG4R641W, 
CSPG4R1179W, and CSPG4R1980H variants. Symbols: filled, schizophrenia; open, unaffected; heterozygous 
carriers of the CSPG4 c.1921C>T p.R641W, c.3535 C>T p.R1179W, and c.5939 G>A p.R1980H. (b) 
Representative sequencing results for heterozygous carriers of the corresponding CSPG4 mutations 
in panel A. 
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Supplementary Figure 4.2 Characterization of iPSC clones and NPCs. (A) RT-PCR of pluripotency 
genes normalized to GAPDH expression levels confirmed down-regulation of exogenous reprogramming 
genes and up-regulation of endogenous stem cell genes, similar to H9 human embryonic stem cells. 
(B) iPSC colonies showed uniform staining for pluripotency markers Nanog, OCT4 and TRA1-81. 
(C) EB differentiation confirmed that iPSCs were capable of generating representative cell types of 
all 3 embryonic layers – endoderm (AFP), mesoderm (Vimentin) and ectoderm (GFAP) (scale bar 
= 20 μm). (D) Karyotyping was performed on all iPSC clones to confirm genomic integrity following 
reprogramming. Shown is a representative karyogram from the iPSC line of subject III-11. (E) NPCs 
were positive for SOX2, Nestin, Vimentin and FOXG1, confirming their forebrain specification (scale 
bar = 10 μm).
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Supplementary Figure 4.3 Characterization of OPCs. NG2+ cells co-expressed the OPC markers 
PDGFRα (A), Olig2 and SOX10 (B) (scale bars = 15 μm). 
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Supplementary Figure 4.4 Aberrant post-translational chondroitin sulphate modification in CSPG4A131T 
patient-derived OPCs. (A) Chondroitin sulphate side chains are specifically cleaved by chondroitinase 
treatment. (B) Representative western blot of biotinylation assay samples of control and patient OPCs 
+/- chondroitinase ABC treatment (intra = intracellular fraction, surf = surface fraction, total = whole cell 
lysate fraction). (C) Quantification of the proportion of chondroitin sulphate-modified NG2 protein. The 
proportion of modified to unmodified NG2 in OPC extracts was determined by normalizing the integrated 
density of modified NG2 (>300 kDa) to the total integrated density of the modified plus unmodified NG2 
bands. Experiments using control (n=9) and patient (n=8) OPCs are shown as aggregated data per 
individual subject (3 control and 3 patient siblings). Error bars in all panels reflect standard errors of the 
mean. Unpaired two-tailed Student’s t-test revealed significantly less modified NG2 protein in whole 
cell lysate (t=2.88, P=0.04), intracellular (t=3.50, P=0.02) and surface fractions (t=3.31, P=0.03). (D) 
Control experiment showing that following chondroitinase ABC treatment, the abundance of 300 kDa 
(unmodified) NG2 in the whole cell lysate fraction is similar between patient and control OPCs (n=6 
control and 6 patient clones, t=0.51, P=0.62). (E) In the absence of biotin (left panel), NG2 protein is 
undetectable in the Neutravidin-purified surface fraction. Furthermore, the absence of detectable actin 
in the surface protein samples confirms the high specificity of the biotin purification. 
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Supplementary Figure 4.5 Raw LI-COR western blot images. Full western blots for NG2 protein 
(upper) and re-blotting for actin (below). (A) Full blot corresponding to Figure 3D (lower half cut vertically 
for processing). (B) Full blot corresponding to Supplementary Figure 4B.
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Supplementary Figure 4.6 CSPG4V901G exhibits abnormal protein localization in U373 human glioma 
cells. Transfection of CSPG4V901G-EGFP expression in human U373 glioma cells that lack endogenous 




Supplementary Figure 4.7 CSPG4P13 pseudogene sequencing controls. (A) Partial alignment 
of CSPG4 Taqman amplicon (hg19 chromosome 15: 75982916-75983072) with homologous 
CSPG4P13 pseudogene sequence (hg19 chromosome 15: 78188526-78188682). Filled arrow 
indicates the position of the CSPG4 c.391G>A variant. Open arrow indicates the differential nucleotide 
distinguishing the flanking CSPG4 sequence from CSPG4P13. (B) Sanger traces of an individual 
carrying the CSPG4 c.391G>A variant while homozygous reference for CSPG4P13. (C) Sanger 
traces of a sample called falsely positive by Taqman genotyping due to a homologous CSPG4P13 
polymorphism (genomic position, hg19 chromosome 15: 78188583) while being homozygous reference 
for CSPG4 c.391G.
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Patient II-1 III-5 III-7 III-9 III-11
Diagnosis 
(DSM)
SZ SZ SZ SZ SZ
Age of onset 
first psychosis
46 18 36 18 15




Supplementary Table 4.1 Discovery Family – Patient characteristics
Chromosome Start position
End 
position Start SNP End SNP MB
2 2686579 17262830 rs11694900 rs17476649 14.576251 0.8809
4 14744996 20524715 rs4464561 rs16869706 5.779719 0.8808
6 164665485 End rs942731 rs9459964 5.675712 0.8809
7 Start 2739017 rs6583338 rs809547 2.692778 0.8852
7 69935641 97595184 rs4717530 rs9692345 27.659543 0.8852
7 148239179 End rs6957883 rs1125769 10.809432 0.8852
10 1147045 9247586 rs4880763 rs1469993 8.100541 0.8808
11 Start 4905155 rs1045454 rs11603903 4.700927 0.8852
11 68289796 129160763 rs11228269 rs4644651 60.870967 0.8852
14 89036519 End rs2116445 rs2583292 18.068524 0.8852
15 39135102 101779863 rs7167406 rs11858464 62.644761 0.8852
16 10480846 76592633 rs7195621 rs12599021 66.111787 0.8826
19 52447068 End rs8105910 rs7910 6.646396 0.8851
Supplementary Table 4.2 Linkage analysis – Affected only model
Chromosome
Genomic 





11 108014748 A G ACAT1 1 0.00042
11 113679159 T C USP28 1 3.0x10-5
15 75983015 C T CSPG4 0 7.8x10-5
16 23080205 C T USP31 2 1.6x10-5
16 31371780 T C ITGAX 2 4.6x10-5






           PCR amplification primers
       Name                           Sequence
               Internal Sanger primers
          Name                           Sequence
CSPG4_ex01_F CTGCCCCAGAGAGGAACAGC CSPG4_ex3a_int_f1 ATGCAGCCACCCTCAATGG
CSPG4_ex01_R CCCCTAACTGGACAGCCTTGG CSPG4_ex3a_int_r1 TCCTCCTCCAGCCTGCAGC
CSPG4_ex02_F GGGCTGGACACAAGGTGAGC CSPG4_ex3a_int_f2 CGTCACCTCCAGGAACACCG
CSPG4_ex02_R CAAGAGCCTGGCAGCAAGC CSPG4_ex3a_int_r2 GGCAGCCAGAGAGTGGGG
CSPG4_ex03a_F TGCCACAGCCTCCAAAGTAGC CSPG4_ex3b_int_f1 CTGGCCCAAGGCTCTGCCAT
CSPG4_ex03a_R GCAGAGTCCGGGTCATAGGC CSPG4_ex3b_int_r1 GGTGCCCTGGCCTCCTTGAG
CSPG4_ex03b_F GCTGGAGGTGTCGGTGACG CSPG4_ex3b_int_f2 ACAAGGCTGTCAGATGGCCAGG
CSPG4_ex03b_R GGCACGTGCACACATGTAACC CSPG4_ex3b_int_f3 GGAGGTACGGGGTGTCTTCCG
CSPG4_ex04_F ACCAGCTGCATGTCTGGCTGC CSPG4_ex3b_int_f4 CCAACCTCGACATCCGCAGTG
CSPG4_ex04_R CTGGCTCCGAGGAGTTGTGAGG CSPG4_ex3b_int_r2 GCCGGCCACGCAACAGG
CSPG4_ex05_F CAGTCTGGGGGTTATACACAGAGAGG CSPG4_ex3b_int_r3 TGGGTGTTCTGAGTGTGCAGTGG
CSPG4_ex05_R GCTCTGAGCCGCGAAGTAGG CSPG4_ex3b_int_r4 CGGCAGGAGAACTCGGTCG
CSPG4_ex06-07_F AGCTGGGGCCTTCCTGGGTA CSPG4_ex10a_int_f1 CCCAGCTGGCTGCAGGGC
CSPG4_ex06-07_R GCCAGGTCCAGGCCTGTGTTT CSPG4_ex10a_int_f2 CATCGAGGTGCAGCTGCGGG
CSPG4_ex08_F GGTCACGCTGCCTCTTTGC CSPG4_ex10a_int_r1 CTGCCACGCTGCTCCCGTTG
CSPG4_ex08_R ACGTCTGCTGCCAGTGATGC CSPG4_ex10a_int_r2 CCGGCTGGGGAACTGTGTGAC
CSPG4_ex09_F CCCAGAGTGGGGCCTGAG CSPG4_ex10b_int_f1 GACCTTGAGGACGGGAGGCT
CSPG4_ex09_R CCCAACCATCAAGCCAGGTC CSPG4_ex10b_int_f2 CTGACTGCCAAGCCCCGCAA
CSPG4_ex10a_F GGGAGGGACAATGGGAGAGG CSPG4_ex10b_int_r1 GTAAGGCTCAGTGGCAAAGTCCA
CSPG4_ex10a_R CCAGCTCGCCAGCATCTAGG CSPG4_ex10b_int_r2 ATCTAGGACGGTGGGGTCCAGG
CSPG4_ex10b_F CTCCGGGTGGTTTCAGATCG
CSPG4_ex10b_R TCTCCAGGCTCGGAGTGAGC
Supplementary Table 4.4 Sanger sequencing primers for CSPG4 open reading frame
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Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection is associ-
ated with a wide variety of neurological complications. Even though SARS-CoV-2 is 
rarely detected in the central nervous system (CNS) or cerebrospinal fluid, evidence is 
accumulating that SARS-CoV-2 might enter the CNS via the olfactory nerve. However, 
what happens after SARS-CoV-2 enters the CNS is poorly understood. Therefore, we 
investigated the replication kinetics, cell tropism, and associated immune responses of 
SARS-CoV-2 infection in different types of neural cultures derived from human induced 
pluripotent stem cells (hiPSCs). SARS-CoV-2 was compared to the neurotropic and highly 
pathogenic H5N1 influenza A virus. SARS-CoV-2 infected a minority of individual mature 
neurons, without subsequent virus replication and spread, despite ACE2, TMPRSS2 and 
NPR1 expression in all cultures. However, this sparse infection did result in the production 
of type-III-interferons and IL-8. In contrast, H5N1 virus replicated and spread very efficiently 
in all cell types in all cultures. Taken together, our findings support the hypothesis that 
neurological complications might result from local immune responses triggered by virus 
invasion, rather than abundant SARS-CoV-2 replication in the CNS.
Importance
Infections with the recently emerged Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-CoV-2) are often associated with neurological complications. Evidence suggests 
that SARS-CoV-2 enters the brain via the olfactory nerve, however SARS-CoV-2 is only 
rarely detected in the central nervous system of COVID-19 patients. Here we show that 
SARS-CoV-2 is able to infect neurons of human iPSC neural cultures, but that this infection 
is abortive, and does not result in virus spread to other cells. However, infection of neural 
cultures did result in the production type III interferon and IL-8. This study suggests that 
SARS-CoV-2 might enter the CNS and infect individual neurons which triggers local 
immune responses that could contribute to the pathogenesis of SARS-CoV-2 associated 
CNS disease.
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Introduction
Neurological manifestations are present in a substantial proportion of patients suffering from 
the respiratory coronavirus disease 2019 (COVID-19). Symptoms comprise loss of smell 
(anosmia), loss of taste (hypogeusia), headache, fatigue, nausea and vomiting111,262,263. 
Additionally, more severe neurological complications such as seizures, confusion, 
cerebrovascular injury, stroke, encephalitis, encephalopathies and altered mental status 
are being increasingly reported in hospitalized patients264–266.
It remains to be established whether the reported neurological manifestations are a direct 
consequence of local invasion of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2) into the central nervous system (CNS), an indirect consequence of the associated 
systemic immune responses, or a combination of both. In human and animal models, it has 
been shown that SARS-CoV-2 is able to replicate in the olfactory mucosa267,268, suggesting 
that the olfactory nerve could function as an important route of entry into the CNS269, as 
observed previously for other respiratory viruses112. Post-mortem brain tissue analyses 
of fatal COVID-19 cases has revealed mild neuropathological changes which might be 
related to hypoxia, as well as pronounced neuroinflammation in different regions of the 
brain270. In the majority of cases, neither SARS-CoV-2 viral RNA, nor virus antigen, could be 
detected in the CNS265,271. In line with this, SARS-CoV-2 viral RNA has rarely been detected 
in the cerebrospinal fluid (CSF) of COVID-19-patients with neurological symptoms110,272,273. 
Together, this suggests that SARS-CoV-2 might enter the CNS but unable to replicate there 
efficiently. 
In the brain, viruses encounter a variety of different cell types such as neurons, astrocytes 
and microglia. Investigations of CNS cell-type specific infection of SARS-CoV-2 have been 
inconsistent274–281. Most studies have investigated virus replication by the detection of viral 
RNA, but have not reported whether infectious progeny viruses are produced during the 
course of infection. In order to investigate replication efficiency, cell tropism and associated 
immune responses of SARS-CoV-2 infection in cells of the CNS, we infected different types 
of human neural cultures. These cultures were differentiated from human induced pluripotent 
stem cells (hiPSCs) along a variety of different neural lineage specifications, which provided 
a unique and flexible platform to study the neurotropism of viruses in vitro. Specifically, 
we directed hiPSC-colonies towards neural progenitor cells (NPCs) via an embryoid body 
stage and subsequently differentiated NPCs to mature neural networks282. In addition, we 
also utilized a rapid neuronal differentiation protocol based on forced overexpression of 
the transcription factor Ngn2 in hiPSCs (Figure 5.1A)40,148 to generate a pure population 
of neurons that we co-cultured with hiPSC-derived astrocytes. Using these specified CNS 
cell types, we directly compared the characteristics of SARS-CoV-2 infection with the 
highly pathogenic H5N1 influenza A virus, a virus with zoonotic potential which is known to 




SARS-CoV-2 does not replicate efficiently in hiPSC-derived neural cell types, 
despite the presence of ACE2, TMPRSS2 and NRP1
To investigate the replication efficiency of SARS-CoV-2, we utilized hiPSC-derived NPCs and 
differentiated these to mature forebrain cortical neural cultures using a previously published 
protocol282 (Figure 5.1A, Supplementary Figure 5.1). The resulting cultures contain a mix 
of electrically active neurons, astrocytes and progenitors. Pure NPC and mixed mature 
neural network cultures were infected with SARS-CoV-2 and H5N1 virus at a multiplicity of 
infection (MOI) of 0.1 and 0.5. At 2, 6, 24 48 and 72 hours post infection (hpi), infectious 
virus titers in the supernatants were determined by endpoint titration. In contrast to H5N1 
virus, no productive infection in SARS-CoV-2 inoculated NPC and mature neural network 
cultures was detected (Figure 5.1B, C). However, in one out of 3 experiments we observed 
an increase in virus titers at 72 hours post infection, which explains the small increase in 
virus titer in the mature neural network cultures. As an alternative to the laborious and time-
consuming differentiation of mature neural networks through embryoid bodies and NPC 
stages, we also employed an established rapid differentiation protocol that yields a pure 
culture of iPSC-derived glutamatergic cortical neurons by overexpressing the transcription 
factor neurogenin-2 (Ngn2)40. We further supplemented the Ngn2-induced neurons with 
hiPSC-derived astrocytes to support their survival and maturation. The final Ngn2 co-
cultures contain astrocytes and functional forebrain cortical neurons that form synapses 
(Figure 5.1A, Supplementary Figure 5.1). SARS-CoV-2 did not replicate efficiently in the 
Ngn2 co-cultures, in contrast to H5N1 virus (Figure 5.1D). As a positive control for virus 
replication, Vero-E6 and MDCK cells were infected with SARS-CoV-2 and H5N1 virus, 
respectively (Figure 5.1E and 5.1F). 
Next, we evaluated the presence of important SARS-CoV-2 entry factors, such as 
angiotensin-converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2) 
and neuropilin-1 (NRP1). In all cultures, there was clear evidence for ACE2, TMPRSS2 and 
NRP1 expression, suggesting cellular susceptibility to SARS-CoV-2 infection (Figure 5.1G, 
Supplementary Figure 5.2). 
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Figure 5.1 SARS-CoV-2 does not replicate in hiPSC derived neural (co-)cultures in contrast to H5N1 
virus. (A) A schematic depiction of the different hiPSC-derived differentiation strategies of the neural 
cultures. hiPSC are differentiated into neural progenitor cells (NPC) and subsequently into mixed neural 
cultures containing mixed neurons and astrocytes. Alternatively, hiPSC are differentiated into excitatory 
neurons by inducing overexpression of Ngn2, these are grown in a co-culture with hiPSC-derived 
astrocytes. Growth kinetics of SARS-CoV-2 or H5N1 virus, in hiPSC-derived (B) NPCs, (C) mature 
neural networks, or (D) Ngn2 co-cultures using a MOI of 0.1 and 0.5. As positive controls (E) MDCK and 
(F) VeroE6 cells were infected with H5N1 virus or SARS-CoV2, respectively. Data represent mean ± 
standard deviation (SD) from three independent experiments. Every growth curve was performed either 
in biological duplicates or triplicates. (G) Presence of the host factors angiotensin-converting enzyme 2 
(ACE2), Transmembrane protease serine 2 (TMPRSS2) and neuropilin-1 (NRP1) of the neural cultures 
was determined with PCR. As controls for the expression of ACE2 and TMPRSS2 bronchus bronchiole 
organoids were used. The uncropped agarose gels are displayed in Supplementary Figure 5.2. 
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SARS-CoV-2 infects MAP2-expressing neurons  
and does not induce cleavage of caspase-3 
To determine whether SARS-CoV-2 was able to infect individual cells, we stained for virus 
nucleocapsid protein (NP) 24 and 72 hpi with a MOI of 0.5. SARS-CoV-2 sparsely infected 
cells in neural cultures at 24 and 72 hpi. Infection was observed in single scattered MAP2+ 
neurons (Figure 5.2A, B and Supplementary Figure 5.3A, C). In one experiment, we 
identified a cluster of MAP2+ cells that stained positively for SARS-CoV-2 NP at 72 hpi 
(Supplementary Figure 5.4A). In the Ngn2 co-cultures, we were only able to detect MAP2+/
NEUN+ neurons positive for SARS-CoV-2 NP, suggesting that SARS-CoV-2 infects only 
mature neurons and does so only sparsely (Supplementary Figure 5.4B). We found no 
convincing evidence of SARS-CoV-2 NP+ cells among SOX2+ NPCs or GFAP+ astrocytes 
(Figure 5.2A-2C). In contrast, H5N1 virus abundantly infected SOX2+ NPCs, GFAP+ 
astrocytes and MAP2+ neurons (Figure 5.2A-C). 
Next, despite the fact that there was no morphological evidence for cell death in the SARS-
CoV-2 infected cultures, we wanted to investigate whether SARS-CoV-2 infection induced 
apoptosis in SARS-CoV-2 NP+ neurons. Therefore, we infected Ngn2 co-cultures with 
SARS-CoV-2 and stained for cleaved caspase-3, an apoptosis marker. We again observed 
that SARS-CoV-2 infected only MAP2+ neurons. Neurons expressing SARS-CoV-2 NP did 
not show accumulation of cleaved caspase-3 (Figure 5.3A, B and Supplementary Figure 
5.4C). 
 Figure 5.2 SARS-CoV-2 infects MAP2+ neurons. (A) Mixed neural culture (scale bar = 100 μm), 
(B) Ngn2 co-cultures (scale bar = 100 μm) and (C) NPCs (scale bar = 50 μm) were infected with a 
MOI of 0.5 with SARS-CoV-2 or H5N1 virus, respectively. 72 hours post infection, the cells were fixed, 
stained for the presence of viral antigen (SARS-CoV-2 NP or H5N1 NP in red). MAP2 (cyan) was used 
as a marker for neurons, astrocytes were identified by staining for glial fibrillary acidic protein (GFAP) 
(green) and SOX2 (green) was used as a marker for NPCs. Cells were counterstained with DAPI (blue) 
to visualize the nuclei. Data shown are representative examples from three independent experiments 
for each culture condition.
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Figure 5.3 SARS-CoV-2 infections does not result in upregulation of cleaved caspase-3. Ngn2 co-
cultures were either (A) mock infected or infected with (B) SARS-CoV-2 at a MOI 0.5 (scale bar = 
50 μm). 72 hours post infection, the cells were fixed and stained for the presence of SARS-CoV-2 
antigen (red) and for the apoptosis marker cleaved caspase-3 (green). Data shown are representative 
examples from two independent experiments.
SARS-CoV-2 infection induces IFN 2/3 and IL-8
To determine the immune response of the neural cultures towards SARS-CoV-2 and H5N1 
virus infection, we measured a panel of antiviral cytokines in the supernatant of infected 
neural cultures at 24 and 72 hours post infection (Figure 5.4). Even though SARS-CoV-2 
infection was scarce, IFNl2/3 was induced in both the mixed neural culture and Ngn2 co-
cultures, but not in NPC cultures. Increased secretion of IL-8 was observed in NPC cultures, 
mixed neural culture and Ngn2 co-cultures. H5N1 virus infection induced both type-III-IFN 
-IFNl1 and -IFNl2/3 in mixed neural cultures and Ngn2 co-cultures, but not among NPCs. 
Furthermore, increased levels of IP-10 were detected only in the H5N1 virus infected neural 
cultures. Similar to SARS-CoV2, H5N1 virus was also able to induce IL-8 in all neural 
cultures. Neither SARS-CoV-2, nor H5N1, virus infection induced type-I-interferon (IFNa/
IFNb) or type-II-IFN (IFNg) or other cytokines such as IL-1b, TNF-a, IL-12p70, GM-CSF or 
IL-10 (Supplementary Figure 5.5).
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Figure 5.4 SARS-CoV-2 infection induces type-III-IFN and IL-8. NPCs, mixed neural cultures and 
Ngn2 co-cultures were infected with SARS-CoV-2 and H5N1 virus at a MOI 0.1. Concentration of 
(A) type-I-interferon (IFN-b), (B) type-II-IFN (IFN-g), (C) type-III-IFN (IFNl1 and IFNl2/3) and (D) the 
antiviral cytokines IP-10 and IL-8 were measured in the supernatant 24 and 72 hours post infection. 
The data are derived from three independent experiments and each experiment was performed either 
in biological duplicates or triplicates. The assay was performed in technical duplicates for each sample. 
The data displayed represent average values of the technical duplicates of each experiment performed. 
Error bars denote mean ± standard deviation (SD). Statistical significance was calculated with a one-
way ANOVA with a Bonferroni post hoc test, the means of the mock infected samples were compared 
to the means of the SARS-CoV-2 and H5N1 virus infected samples at 24 and 72 hours post infection. 




SARS-CoV-2 replicated poorly in all three types of hiPSC-derived neural cultures used 
in our experiments, which contrasts largely to H5N1 virus, which replicated efficiently to 
high titers. Even though important entry factors for SARS-CoV-2 are expressed in all of 
the cultures used, SARS-CoV-2 infected a very small proportion of cells without evidence 
of subsequent spread. Additionally, we did not observe SARS-CoV-2 induced neuronal 
cell death, indicated by a lack of co-labeling with apoptosis-marker cleaved caspase 3 in 
SARS-CoV-2 NP+ neurons. However, SARS-CoV-2 infection did induce type-III-IFN and 
IL-8 production.
Evidence is accumulating that SARS-CoV-2 enters the CNS via the olfactory nerve267–269, 
a pathway that is also used by influenza A viruses to enter the CNS in many mammals 
including humans112,293. H5N1 virus spreads efficiently to the CNS via the olfactory nerve 
in experimentally inoculated ferrets and subsequently replicates very efficiently in the 
CNS283,285,294. Unlike H5N1 virus infection, SARS-CoV-2 is rarely detected in the CNS of fatal 
COVID-19 patients or experimentally inoculated animals110,270–273. In addition, only a handful 
of case reports of SARS-CoV-2 induced encephalitis have been reported295,296..In vitro 
studies have mainly focused on the ability of SARS-CoV-2 to infect cells of the CNS based 
on the detection of viral RNA or viral antigen276,277,280,297,298 but not many have investigated 
replication efficiency in time by measuring infectious virus titers275. So far, several studies 
showed limited infection of neurons in hiPSC derived brain organoids280 and brainspheres277, 
without efficient SARS-CoV-2 replication. So far, only efficient replication has been shown in 
choroid plexus organoids especially within choroid plexus epithelium cells275,298. Altogether, 
these observations are consistent with our findings of poor SARS-CoV-2 replication in 
hiPSC-derived NPCs, neurons and astrocytes, and supports a pathophysiological model 
whereby SARS-CoV-2 invades the CNS, but does not replicate efficiently in CNS cell types. 
However, one caveat of our study is that other cells such as microglia, oligodendrocytes and 
vascular cells (pericytes, endothelial cells) are not present. Therefore, we cannot exclude 
that SARS-CoV-2 can infect and possibly replicate efficiently in other cells of the CNS or 
neuronal cell types such as cortical PV interneurons, midbrain or hindbrain cell types. 
Despite the low proportion of SARS-CoV-2 infected cells and the fact that infection seemed 
to be abortive in the hiPSC-derived neural cultures, we found evidence for cellular immune 
activation. In particular, SARS-CoV-2 infection of the neural cultures resulted in the 
induction of type-III-IFN especially IFNl2/3, but not type-I-IFN or type-II-IFN. This result 
is in accordance with earlier reports suggesting that SARS-CoV-2 triggers only very mild 
type-I and type-II-IFN responses, but does trigger a robust type-III-IFN response in cell 
culture, human airway epithelial cells, ferrets and SARS-CoV-2 infected individuals299,300. 
In addition, IL-8—a chemotactic factor that attracts leukocytes—was induced in all hiPSC-
derived cultures. In lung tissue and peripheral venous blood serum of SARS-CoV-2 infected 
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patients, elevated levels of IL-8 are associated with severe COVID-19301–303. Furthermore, 
IL-8 has been detected in the CSF of SARS-CoV-2 patients who developed encephalitis, 
which might be induced by the SARS-CoV-2 associated brain immune response, since 
SARS-CoV-2 RNA could not be detected in the CSF304. However, how exactly these 
cytokines contribute to the in vivo neuroinflammatory process, and if they are directly 
triggered by SARS-CoV-2 entry into the CNS needs further investigations. 
Highly pathogenic H5N1 virus replication has been reported in vivo283,285,287,288,305 and in vitro 
across several different types of human and mouse neural cell cultures290–292, including the 
human neuroblastoma line SK-N-SH26, suggesting this virus is neurotropic. This fits with our 
observation that H5N1 virus replicates productively and spreads throughout hiPSC-derived 
neural cultures, infecting NPCs as well as mature neurons and astrocytes. H5N1 virus 
infection also results in the upregulation the type-III-IFN IFNl1 and IFNl2/3, as well as the 
antiviral cytokines IL-8 and IP-10. IP-10 has been detected in the CSF of influenza A virus 
infected patients and was found to be elevated in the brains of mice experimentally infected 
with H5N1 virus306. However, the mechanism by which H5N1 virus achieves abundant 
virus replication and robust induction of pro-neuroinflammatory cytokines remains poorly 
understood.
Overall, our data fit with clinical findings concerning the ability of these viruses to cause 
acute CNS disease. In both humans and mammalian animal models, H5N1 virus is 
able to invade and replicate in cells of the CNS, including neurons, resulting in an acute 
(meningo)-encephalitis307–309. In contrast, even though evidence exists that SARS-CoV-2 is 
able to spread to the CNS via the olfactory nerve267–269 in SARS-CoV-2 infected patients or 
experimentally infected animal models, virus is rarely detected in the CNS or associated 
with acute encephalopathies110,272,273.
Altogether, our findings reveal that replication of SARS-CoV-2 in CNS cell types is very 
limited, which is in contrast to the efficient replication and spread of H5N1 virus. Although 
the mechanistic pathogenesis of SARS-CoV-2 associated CNS disease remains poorly 
understood, this study supports the hypothesis that SARS-CoV-2 entry into the CNS and 





VeroE6 (ATCC® CRL 1586TM) cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Lonza, Breda, the Netherlands) supplemented with 10% fetal calf serum (FCS, 
Sigma-Aldrich, St. Louis, MO, USA), 10mM HEPES, 1.5 mg/ml sodium bicarbonate, 100 IU/
ml penicillin (Lonza, Basel, Switzerland) and 100 μg/ml streptomycin (Lonza). Madin-Darby 
Canine Kidney (MDCK) cells were maintained in Eagle minimal essential medium (EMEM; 
Lonza) supplemented with 10% FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM 
glutamine, 1.5 mg/ml sodium bicarbonate, 1 mM, 10 mM HEPES and 0.1 mM nonessential 
amino acids. All cell lines were grown at 37 °C in 5% CO2. The medium was refreshed every 
3–4 days, and cells were passaged at >90% confluence with the use of PBS and trypsin-
EDTA (0.05%). The cells were routinely checked for the presence of mycoplasma.
Differentiation of iPSCs to NPCs and mature neural cultures
Human induced pluripotent stem cells (iPSCs) [WTC-11 Coriell #GM25256, obtained from 
the Gladstone Institute, San Francisco, USA] were differentiated to NPCs as previously 
described2 with slight modifications. After passage 3, NPC cultures were purified using 
fluorescence-activated cell sorting (FACS) as described previously146. Briefly, NPCs were 
detached from the culture plate and resuspended into a single cell solution. CD184+/CD44-/
CD271-/CD24+ cells were collected using a FACSaria III (BD bioscience) and expanded 
in NPC medium (Table 5.1). NPCs were used for experiments between passage 3 and 7 
after sorting or differentiated to neural networks. For differentiation towards mature neural 
cultures, NPCs were grown in neural differentiation medium (Table 5.1) for 6-8 weeks to 
achieve mature neural networks 282 and subsequently used for experiments, after week 4 
only half of the medium was refreshed. Cultures were kept at 37 °C/5%CO2 throughout the 
entire differentiation process.
Differentiation of iPSCs to Ngn2 co-cultures
iPSCs were directly differentiated into excitatory cortical layer 2/3 neurons by forcibly 
overexpressing the neuronal determinant Neurogenin 2 (Ngn2)40,148. To support neuronal 
maturation, hiPSC-derived astrocytes were added to the culture in a 1:1 ratio. At day 3, 
the medium was changed to Ngn2-medium (Table 5.1). Cytosine b-D-arabinofuranoside 
(Ara-C) (2 µM; Sigma, C1768) was added once to remove proliferating cells from the culture 
and ensure long-term recordings of the cultures. From day 6 onwards, half of the medium 
was refreshed three times per week. Cultures were kept at 37 °C/5%CO2 throughout the 
entire differentiation process.
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Viruses 
The SARS-CoV-2 isolate (isolate BetaCoV/Munich/BavPat1/2020; European Virus Archive 
Global #026V-03883; kindly provided by Dr. C. Drosten) was previously described by 
Lamers et al.310,311 The zoonotic HPAI H5N1 virus (A/Indonesia/5/2005) was isolated from a 
human patient and the virus was propagated once in embryonated chicken eggs and twice 
in MDCK cells.
Virus Titrations
The SARS-CoV-2 titers were determined by endpoint dilution on VeroE6 cells, calculated 
according to the method of Spearman & Kärber and expressed as 50% tissue culture 
infectious dose/ml (TCID50/ml). SARS-CoV-2 virus titers were determined by preparing 10-
fold serial dilutions in triplicates of supernatants in Opti-MEM containing GlutaMAX. Dilutions 
supernatants were added to a monolayer of 40.000 VeroE6 cells/well in a 96-well plateand 
incubate at 37°C. After 5 days the plates were examined for the presence of cytopathic 
effect (CPE). Virus titers of HPAI H5N1 were determined by endpoint dilution on MDCK as 
described previously312. In short, 10-fold serial dilutions of cell supernatant in triplicates were 
prepared in Influenza infection medium which consists of EMEM supplemented with 100 
IU/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate, 
10 mM HEPES, 1× (0.1 mM) nonessential amino acids, and 1 μg/μl TPCK-treated trypsin 
(Sigma-Aldrich). Prior to adding the virus dilutions to the MDCK cells, the cells were washed 
once with plain EMEM-medium to remove residual FCS. 100 µl of the diluted supernatants 
was used to inoculate 30.000 MDCK cells/well in a 96-well plate. After one hour, the inoculum 
was removed and 200 µl fresh influenza infection medium was added. Four days after 
infection, supernatants of the infected MDCK cells were tested for agglutination. 25 µl of the 
supernatant were mixed with 75 µl 0.33% turkey red blood cells and incubated for one hour 
at 4°C. The titers of infectious virus were calculated according to the method of Spearman & 
Kärber and expressed as TCID50/ml. All experiment with infectious SARS-CoV-2 and H5N1 
virus were performed in a Class II Biosafety Cabinet under BSL-3 conditions at the Erasmus 
Medical Center. The initial 1:10 dilution of cell supernatant resulted in a detection limit of 
101.5 TCID50/ml.
Replication Kinetic
Before infection of neural progenitors, network neurons and NGN2 neurons, supernatant 
was removed and cells were infected with SARS-CoV-2 and H5N1 virus at the indicated 
multiplicity of infection (MOI). As control for active virus replication, VeroE6 and MDCK cells 
were infected with SARS-CoV-2 and H5N1 virus, respectively. Before virus infection, the 
VeroE6 cells were washed with SARS-CoV-2 infection medium (DMEM supplemented with 
2% FBS and 100 IU/ml penicillin, 100 μg/ml streptomycin) and MDCK cells were washed 
with influenza infection medium. After 1 hours of incubation at 37°C, the inoculum was 
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removed and replaced with fresh medium and old medium in a 1:1 ratio. After removing 
the inoculum from VeroE6 and MDCK cells, SARS-CoV-2 infection medium and influenza 
infection medium, respectively, were added to the cells. At the indicated timepoints an 
aliquot of the supernatant was collected for subsequent virus titration. All experiments were 
performed in biological triplicates and either in technical duplicates or triplicates.
PCR Validation of ACE2, TMPRSS2 and NRP1 expression
RNA was isolated from the neural cultures and VeroE6 cells using the High Pure RNA 
Isolation Kit (Roche). The concentration of RNA was determined using Nanodrop. 2.5µg 
of RNA was reverse transcribed into cDNA using the SuperScript III reverse transcriptase 
(Invitrogen) according to the manufacturers’ protocol. cDNA of bronchus-bronchiol organoids 
were kindly provided by Anna Z. Mykytyn. Presence of ACE2, TMPRSS2, NRP1 and ACT 
was evaluated by amplified these genes with gene specific primers (Table 5.2) by PCR. 
Gene products were visualized on a 2% agarose gel which was stained with SYBR Safe. 
PCR products of the genes were sequenced to validate that the right product was amplified. 
Multiplexed bead-assay for Cytokine Profiling
Cytokines were measured using the LEGENDplex™ Human Anti-Virus Response 
Panel (BioLegend). The kit was used according to manufacturer’s manual with an additional 
fixing step. After adding the SA-PE and performing the washing steps, the supernatant and 
the beads were fixed with formalin for 15 minutes at room temperature and washed twice 
with the provided wash buffer. This ensures that all pathogens are not infectious.
Immunofluorescent labeling
Cells were fixed using 4% formalin in PBS and labeled using immunocytochemistry. Primary 
antibody incubation was performed overnight at 4°C. Secondary antibody incubation was 
performed for 2 hours at room temperature. Both primary and secondary antibody incubation 
was performed in staining buffer [0.05 M Tris, 0.9% NaCl, 0.25% gelatin, and 0.5% Triton 
X-100 (Sigma, T8787) in PBS (pH 7.4)]. Primary antibodies and their dilutions can be 
found in Table 5.3. Secondary antibodies conjugated to Alexa-488, Alexa-647 or Cy3 were 
used at a dilution of 1:400 (Jackson ImmunoResearch). Nuclei were visualised using DAPI 
(ThermoFisher Scientific, D1306). Samples were embedded in Mowiol 4-88 (Sigma-Aldrich, 
81381) and imaged using a Zeiss LSM 800 confocal microscope (Oberkochen, Germany).
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Name Reagents Manufacturer, catalogue number
NPC Medium Advanced DMEM/F12 ThermoFisher Scientific, 1634010
 1% N-2 Supplement ThermoFisher Scientific, 17502048
 2% B-27 minus RA Supplement ThermoFisher Scientific, 12587010
 1 μg/ml Laminin Sigma-Aldrich, L2020
 1% Penicillin-Streptomycin ThermoFisher Scientific, 15140122
 20 ng/ml basic Fibroblast Growth Factor Merck, GF003AF
Neural Neurobasal medium ThermoFisher Scientific, 21103049
Differentiation 1% N-2 Supplement ThermoFisher Scientific, 17502048
Medium 2% B-27 minus RA Supplement ThermoFisher Scientific, 12587010
1% MEM NEAA ThermoFisher Scienfitic, 11140035
 2 μg/ml Laminin Sigma-Aldrich, L2020
 1% Penicillin-Streptomycin ThermoFisher Scientific, 15140122
20 ng/ml BDNF ProSpec, CYT-207
20 ng/ml GDNF ProSpec, CYT-305
 1 μM db-cAMP Sigma-Aldrich, D0627
200 μM ascorbic acid Sigma-Aldrich, A5960
Ngn2 medium Neurobasal medium ThermoFisher Scientific, 21103049
 2% B-27 minus RA Supplement ThermoFisher Scientific, 12587010
 2 μg/ml Laminin Sigma-Aldrich, L2020
 1% Glutamax ThermoFisher Scientific, 35050061
 10 ng/ml NT3 PeproTech, 450-03
 20 ng/ml BDNF ProSpec, CYT-207
 1% Penicillin-Streptomycin ThermoFisher Scientific, 15140122
Table 5.1 Overview of media used during differentiation.
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ACE2-FWD GGGATCAGAGATCGGAAGAAGAAA 60 124 1
ACE2-REV AGGAGGTCTGAACATCATCAGTG 1
b-ACTIN-FWD CCCTGGACTTCGAGCAAGAG 60 153 1
b-ACTIN-REV ACTCCATGCCCAGGAAGGAA 1
TMPRSS2-FWD AATCGGTGTGTTCGCCTCTAC 60 106 1
TMPRSS2-REV CGTAGTTCTCGTTCCAGTCGT 1
NRP1-FWD GACTGGGGCTCAGAATGGAG 60 187
NRP1-REV ATGACCGTGGGCTTTTCTGT
Table 5.2 Overview of primers used
Antibody Dilution Manufacturer, catalogue number
SARS-CoV-2- Anti NP 1:500 Sino Biological, 40143-MM05
SOX2 1:250 Millipore, AB5603
NEUN 1:100 Merck, ABN78
GFAP 1:200 Millipore, AB5804
MAP2 1:200 Synaptic Systems, 188004
H5N1- Anti NP 1:1000 EVL, EBS-I-047, Clone Hb65
Cleaved Caspase-3 1:100 Cell Signaling Technologies, 9661S
Beta III Tubulin (TUJ1) 1:200 Millipore, AB9354
PSD-95 1:100 Thermo Scientific, MA1-046
Synapsin 1:100 Synaptic Systems, 106 103
FOXG1 1:200 Abcam, 18259
Table 5.3 Antibodies used for immunocytochemistry. 
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Supplementary Figures
Supplementary Figure 5.1 Immunohistological characterization of neural cultures. (A) NPC cultures 
that were used to generate mixed neural cultures are positive for FOXG1 (green), indicating a forebrain 
identity. TUJ1, a marker for immature neurons, is hardly detected in cells, suggesting a pure population 
of precursor cells (scale bar = 100 µm). (B) Eight-week old mixed neural cultures contain astrocytes 
(GFAP, green) and neurons that stain positive for MAP2 (cyan) and the mature neuronal marker NEUN 
(red) (scale bar = 100 µm). (C) Neurons express pre- (synapsin, red) and post-synaptic (PSD95, green) 
proteins that co-localize with MAP2 (cyan), suggesting the formation of synapses (scale bar = 10 µm) 
(D) Neurons (MAP2, cyan) in three-week old Ngn2 co-cultures express FOXG1 (green) and NEUN 
(red), indicating that the cells have developed towards mature cortical forebrain neurons (scale bar = 
50 µm). (E) Ngn2-neurons express pre- (synapsin, red) and post-synaptic (PSD95, green) proteins that 
co-localize with MAP2 (cyan), suggesting the formation of synapses (scale bar = 10 µm).
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Supplementary Figure 5.2 Expression of important entry factors for SARS-CoV-2, original pictures 
form the gels. Expression of (A) ACE2 with amplicon size 124bp (B) NRP1 with amplicon size 187 
bp (C) TMPRSS2 with amplicon size 106bp (D) ACT with amplicon size 153bp from one out of two 
independent experiment are shown. The important bands with the correct sizes of the amplicon were 
cropped and are represented in Figure 1G. 
129
SARS-CoV-2 dynamics in iPSC-derived neural cultures
Supplementary Figure 5.3 SARS-CoV-2 infects MAP2+ neurons. (A) Mixed neural culture (scale 
bar = 100 μm) and (B) Ngn2 co-cultures (scale bar = 100 μm) were infected with a MOI of 0.5 with 
SARS-CoV-2 or H5N1 virus, respectively. 24 hours post infection, cells were fixed and stained for the 
presence of viral antigen (SARS-CoV-2 NP or H5N1 NP in red). MAP2 (cyan) was used as a marker 
for neurons, astrocytes were identified by staining for glial fibrillary acidic protein (GFAP) (green). DAPI 




Supplementary Figure 5.4 SARS-CoV2 infects NEUN+ neurons and does not induce cleaved- 
caspase-3 expression. (A) One focus of multiple infected cells was identified (scale bar = 100 μm). (B) 
The neurons in the Ngn2 cultures consist of a homogeneous population of mature NEUN+ neurons 
(scale bar = 50 μm). (C) High magnification image of a SARS-CoV-2 infected cell in which no cleaved-
caspase-3 is visible (scale bar = 20 μm). 
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Supplementary Figure 5.5 SARS-CoV-2 infection as well as H5N1 virus infection results in modest 
immune responses. The concentration of the cytokines which were measures in the supernatant of 
SARS-CoV-2 or H5N1 virus infected (A) NPCs, (B) mixed neural cultures and (C) Ngn2 co-cultures are 







Since the establishment of human induced pluripotent stem cell (iPSC)-technology in 
2007, the protocols to obtain iPSC-derived neural cells have improved tremendously. Early 
protocols considered neurons mature when they could fire a single action potential. More 
recent studies have demonstrated iPSC-derived brain organoids that exhibit waves of 
synchronized electrical activity313. The work described in this thesis attempts to expand this 
toolbox and shows the enduring potential of iPSC technology for investigating human brain 
disorders. 
In Chapter 2 we present a novel protocol to efficiently differentiate iPSCs to functional 
astrocytes that support the formation and maturation of neuronal networks. This provides 
the opportunity to mature iPSC-derived neurons in vitro by supplementing human astrocytes 
instead of their rodent counterpart and thereby create a fully human co-culture system. 
Moreover, we were able to show reciprocal effects of co-culture on both astrocytes and 
neurons, which resulted in a more mature cellular identity of both cell types.
In vitro culture conditions are designed to mimic physiological development through 
recapitulation of key aspects of the in vivo environment. Chapter 3 describes a model in 
which we transplant iPSC-derived neural cells into the brain of neonatal immunodeficient 
mice, providing the human cells with a more physiological environment to enhance their 
development. IPSC-derived astrocytes maintain their hominid characteristics after murine 
transplantation and develop a more complex morphology compared to 2D monolayer 
culture. Furthermore, we leveraged this model for preclinical screening of human antisense 
oligonucleotide (ASO) therapy for Angelman Syndrome (AS). We show that we can 
selectively reactivate the human paternal UBE3A allele by administrating an ASO targeting 
UBE3A-ATS to immunodeficient mice transplanted with AS patient-derived neurons. 
An example of how iPSCs can be used to study familial schizophrenia is described in 
Chapter 4. By performing linkage analysis combined with whole exome sequencing and 
reprogramming iPSC lines from patients and their unaffected siblings, we were able to identify 
rare genetic variants in patients and a cellular phenotype in iPSC-derived oligodendrocyte 
lineage cells. Mutant Chondroitin Sulfate Proteoglycan 4A131T/V901G (CSPG4) showed defects 
in membrane trafficking, and OPCs from patients with the CSPG4A131T mutation were less 
viable and exhibited decreased myelination potential. Consistent with these findings, 
diffusion tensor imaging of affected CSPG4A131T mutation carriers displayed a reduction in 
brain white matter integrity. This study provides evidence in support of oligodendrocyte 
precursor cell dysfunction as a novel candidate mechanism of schizophrenia and supports 
the validity of combining family genetics and iPSC modeling to unravel underlying biological 
mechanisms of psychiatric disorders.
135
General Discussion
The value of having efficient access to an unlimited source of iPSC-derived neural cells is 
illustrated in Chapter 5 by our work with Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-CoV-2). The current COVID-19 pandemic has shown the importance of having a 
thriving scientific community. Neurological symptoms reported by COVID-19 patients sparked 
research into possible SARS-CoV-2 infections in the central nervous system (CNS). We 
infected different types of iPSC-derived neural cultures with SARS-CoV-2 to investigate the 
kinetics, cell tropism and associated immune response after infection. Definitive evidence of 
SARS-CoV-2 infection was found in only a small proportion of neurons without evidence for 
subsequent spread to other cells. We did not find evidence for infection in neural precursor 
cells (NPCs) or astrocytes. However, we did observe a strong increase of a subset of pro-
inflammatory cytokines, raising the possibility that the neurological symptoms observed in 
patients might result from a heightened immune response to SARS-CoV-2 infection.
During the past decade, advances in iPSC technology have generated strong interest 
among biomedical researchers, especially in the field of neuroscience. IPSC-derived neural 
cells have been enthusiastically adopted to model human brain diseases. These cells 
contain the human genome of the individuals from whom the iPSCs are reprogrammed, 
and allow for elegant experimental designs through rapid advances in genome editing. 
This has created a greatly expanded opportunity to study the human brain, a tissue that 
previously was largely inaccessible for live cellular studies. Accordingly, many scientists 
have refocused their work on iPSC-based studies and published a plethora of studies 
utilizing this technique314. Although brain disease modeling with iPSCs is an expensive and 
technically challenging endeavor, it offers great potential to answer fundamental questions 
about human neural cell functioning and development that have not been solved using 
other approaches. Consequently, interest in this technique continues to increase, as a 
model system for therapeutic drug discovery315 or, for example, as a personalized treatment 
option for Parkinson’s disease through delivery of iPSC-derived neural cells316. To critically 
appraise their use, and position iPSC-technology in the wider technical and conceptual 
setting of brain research, an overview describing the current state of the field and guidance 
for designing iPSC-studies is described below.
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Biological variability in iPSC cultures
Variability and reproducibility are a concern in all fields of experimental biology. The source 
for this variability can be both biological and technical. IPSC lines from different individuals 
have a different genetic background and will behave differently in vitro due to biological 
variability. Two iPSC clones created from one individual should be biologically identical, 
however due to technical variability these two clones can still behave different in seemingly 
identical culture conditions. These sources of variability contribute to the observed cellular 
heterogeneity in cultures used for experiments and should be taken into account when 
designing experiments. From a biological point of view, neurodevelopmental and psychiatric 
disorders are associated with subtle cellular phenotypes that could easily be lost in batch-
to-batch variability. Understanding how genetic background and culture conditions affect 
variability and reproducibility is essential when attempting to identify disease-related 
phenotypes using iPSC-lines carrying pathogenic mutations or risk genotypes.
Traditional approaches to create iPSCs relied on random integration of the “Yamanaka 
factors” into somatic cells, causing every iPSC-clone from an individual to have a slightly 
different genetic identity. Integration-free methods circumvented this problem, however 
mutations that are not present in the parental line can still be detected317. These are likely 
created during the initial cell divisions of the founder population of iPSCs. Genetic stability 
is reduced during the process of converting somatic cells to iPSCs – it is estimated that 
10% of all somatic mutations observed in iPSCs are sub-clonal and not observed in the 
parental line318,319. Although the majority of these mutations likely have no impact on gene 
expression or functioning, quality control checks for every iPSC-clone being considered 
for use in experiments should be performed, minimally to exclude the presence of gross 
genetic abnormalities and verify their ability to differentiate towards all three germ-layers.
When converting terminally differentiated somatic cells to iPSCs, the epigenetic landscape 
of the donor cell is transformed to resemble that of embryonic stem cells. Pluripotency genes 
become expressed and genes that previously determined donor cell identity are silenced 
through the methylation of their promotor region. It has been established that there can be 
residual expression of somatic genes due to incomplete DNA methylation, creating a so-
called epigenetic memory of the somatic cell type of origin320,321. These residual epigenetic 
markings tend to bias iPSCs towards easier differentiation along the lineage of the somatic 
cell type of origin. For example, iPSCs derived from blood will more easily differentiate 
towards hematopoietic  progenitors322.  Therefore, when designing studies using iPSCs, it 
is not only important to consider the desired experimental cell type, but also the somatic 
donor cells used to create the iPSCs. Different cellular origins will already be responsible 
for epigenetic variation between iPSC-lines and could obscure potential cellular differences 
between lines. Notably in Chapter 3, we demonstrate that the imprinting of the paternal 
UBE3A allele in iPSC-derived neurons is preserved during the creation of iPSCs. A more 
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extensive study looked into multiple known imprinted genes in the iPSC-lines and donor 
cells of four individuals and found that imprinting is conserved in most actively transcribed 
genes323. Quality control screening of iPSC-clones helps to circumvent these problems as 
clone-specific effects heavily influence aberrant methylation at CpG sites in a non-random 
manner324.
The biggest source of biological variability arises from differences in the genetic background 
of donors. IPSC-clones of a single individual created from different somatic cell types, 
such as blood or skin, are more similar in their expression profile than iPSC-lines created 
from identical somatic cell types from different donors323. In iPSC-based studies of genetic 
disorders, one of two potential strategies is often implemented to circumvent these issues. 
One approach is to create iPSC-lines from multiple donors, ideally with a similar genotype 
at the locus of interest, in an effort to filter out the effect of different genetic backgrounds and 
identify the effect of the putatively causal genetic variant on a cellular phenotype. Alternatively, 
It is possible to create or correct a known causal variant in an iPSC-line using gene editing 
techniques such as CRISPR/Cas996 to create so-called isogenic lines – two cell lines that 
only differ in their genetic sequence at a locus of interest. This technique makes it possible 
to precisely edit the genome by directing the CRISPR/Cas9 complex to a specific location 
in the genome via a single guide RNA (sgRNA). The resulting double-stranded break is 
repaired based either on an exogenously supplied template or through nonhomologous DNA 
end joining (NHEJ). Using this approach, knock-out lines for a specific gene are created in 
an otherwise healthy genetic background. Template-based single nucleotide editing is done 
in order to introduce putatively causal missense variants and quantify their contribution to 
an observed cellular phenotype in a susceptible genetic background, or introduce a causal 
variant into an iPSC line with a healthy genetic background325. Even though targeted gene 
editing using CRISPR/Cas9 in human iPSCS remains a laborious process, it has become 
widely adopted in the iPSC field. As an alternative to targeted editing, CRISPR/Cas9 has 
evolved into a tool to manipulate gene expression using CRISPR interference (CRISPRi) 
and CRISPR activation (CRISPRa)326, respectively decreasing or increasing the expression 
of a gene-of-interest. For example, this approach has been used to successfully modulate 
the top-ranked schizophrenia-associated expressive trait loci, converging on a synaptic 
phenotype327.
When iPSC-lines are available to ensure proper controls and adequate sample size, this 
approach to cellular disease modeling is an excellent tool to answer fundamental questions 
about cellular processes and, potentially, unravel the etiology of genetic brain disorders. 
However, not all aspects of human brain development can be modeled in vitro using iPSCs. 
Attempting to link cellular phenotypes in vitro to symptoms observed in psychiatric patients 
remains challenging due to the complex and temporal nature of psychiatric symptoms. For 
example, the substantially reduced viability observed in iPSC-derived NPCs of patients with 
bipolar disorder is difficult to reconcile with their normal brain development328. It is important 
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to consider what phenotype is intended to be pursued for a given model and whether such 
a phenotype can be effectively recapitulated using iPSCs. Many protocols exist to create 
iPSC-derived neural cells – depending on the desired cell type and research question, 
some approaches are more suitable than others. 
Technical variability in iPSC cultures
Batch to batch variability is a problem in all cell culture studies, even in widely used primary 
clonal cell lines329. Differentiation of iPSCs to mature neural cells typically takes several 
months. Different types of medium guide cells through progressive developmental stages 
until they mature into the desired cell type. Due to their lengthy nature and multiple stages 
during these protocols, variance in experimental outcomes is easily acquired through 
technical variability. Extensive literature has been written on how to differentiate iPSCs 
along different neural lineages. Early neural differentiation protocols often showed relatively 
low and variable yields of the desired cell type. During the past decade, substantial progress 
has been made in the efficiency and reproducibility of these protocols.
Already at the iPSC stage, different protocols exist to maintain pluripotency. Traditional 
approaches make use of a mouse or human feeder layer of embryonic fibroblasts1. This 
feeder layer promotes pluripotency and helps maintain genetic stability. Growing iPSCs on 
a feeder layer is labor intensive and difficult to scale. Researchers have developed feeder-
free systems by replacing the feeder layer with extracellular matrix proteins such as Matrigel 
and growing the iPSCs in Essential 8 or MTeSR medium, significantly reducing the required 
effort to maintain and expand iPSCs. However, when grown in these conditions, genomic 
stability of iPSCs is often reduced330. The latest iteration of feeder-free culture conditions 
uses StemFlex medium. In these conditions, iPSCs are more stress resilient, enhancing the 
efficiency of gene editing techniques331.
Among the biggest challenges for realizing the therapeutic discovery potential of iPSC is 
translation of phenotypes observed in patients or putative causative genetic variants to 
cellular phenotypes that can be measured in vitro. The formulated hypothesis combined 
with practical and technical constraints will already determine certain decisions in 
experimental design and donor or cell type. To illustrate this with an example from this 
thesis, when the goal is to identify cellular phenotypes in a family with a high incidence 
of schizophrenia, in which the affected individuals carry a mutation in CSPG411, creating 
iPSCs from affected and unaffected siblings is an obvious choice. Alternatively, it is possible 
to create this identified genetic variant in a control iPSC-line, in which the effect of the 
variant can be studied outside a known susceptible genetic background, or correct the 
mutation in a patient-derived iPSC-line. Since CSPG4/NG2 is highly expressed in OPCs, 
it makes sense to utilize protocols that are designed to obtain iPSC-derived OPCs. The 
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processing of (mutant) NG2 in these cells can be studied in 2D mono-layer cultures, a 
relatively simple culture system. Their maturation towards myelinating oligodendrocytes is 
best done in the presence of unmyelinated axons, adding an additional layer of complexity 
to the culture system. 
An ideal culture system models the relevant aspects of a disorder and is simple enough to 
minimize technical variability. Brain cells require the physical presence of other neural cells 
to properly develop, e.g. neurons are unable to repetitively fire action potentials or develop 
into functional neuronal networks without the presence of astrocytes73 and astrocytes show 
altered expression and increased maturity in co-culture with neurons (this thesis). Due to 
these reciprocal inductive interactions during the development of neural cells, iPSC-derived 
neural cultures typically require a heterogeneous population of cells. This creates more 
mature cells, but increases the chances of variability between cultures. Before initiating 
differentiation, a homogenous culture of iPSCs shows little technical variability when grown 
and expanded in defined culture conditions. During the differentiation towards neural 
cells these cultures become less homogenous and more batch-to-batch variation occurs. 
When differentiating iPSCs to NPCs, not all NPCs in the culture will be in the exact same 
developmental window, emphasized by the emergence of structural differences by NPCs 
forming neural rosettes. The emergence of these structures is heavily influenced by culture 
conditions, they will only form at a certain confluency of cells. Moreover, it is likely that 
not all cells will have fully committed towards the neural, or even ectoderm, lineage. The 
amount of variability in this process will vary between iPSC-lines and clones, potentially 
masking relevant cellular phenotypes. Variability at a progenitor stage can be reduced 
through magnetic or fluorescence activated cell sorting, purifying the cell population based 
on surface markers146,332. A positive selection for NPC-markers combined with a negative 
selection for mature glial, neuronal and mesenchymal marker results in a more homogenous 
NPC population. This greatly reduces variability between different batches and iPSC-clones, 
facilitating in the identification a potential phenotype in the terminally differentiated cultures.
The large stereotypically-folded neocortex is one of the striking features of the human brain. 
iPSC-derived brain organoids attempt to add this feature to the toolbox for investigating 
human brain disorders in vitro. 3D organoids add another layer of complexity to iPSC models 
of human brain development and, consequently, show increased variability compared 
to 2D models333. Brain organoids exhibit features not observed in 2D neural cultures: 
dendritic spines are only observed in 3D models334, organoids recapitulate key events 
of cortical development such as cortical layering335,  natural development of myelinating 
oligodendrocytes is only observed in brain organoids336. Organoid models largely rely 
on the self-organizational capability of neural stem cells. In a free-floating environment, 
stochastic asymmetrical division of neural stem cells gives rises to a three-dimensional 
tissue containing different mature neural cells in organized structures that resemble early 
brain development. Depending on the brain region of interest, it is possible to introduce 
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regional specificity using defined media337, or to fuse organoids with different regional 
identities to model cortico-striatal or -thalamic connections, then called assembloids338,339. 
Researchers are adopting strategies to further enrich brain organoids with features relevant 
to their studies by fusing them with cells or tissue types that they are currently lacking, 
e.g. blood vessels340, microglia341, choroid plexus cells342, or muscle tissue to look at the 
functional output of brain organoids334.
Compared to 2D cultures, these approaches yield more mature cells. However, organoids 
have the disadvantage that they are highly heterogeneous. Early protocols introduced 
features not seen previously in iPSC-derived neural cultures, but their efficiency was 
limited due to variability in cell composition, morphology and tissue identity343. Technical 
refinements have addressed some issues regarding variability333,344. Nevertheless, it 
remains a significant issue when growing brain organoids. Despite these, and likely future 
refinements, it is currently still necessary to take this expected variability in account when 
designing experiments using iPSC-derived brain cells, both in 2D and 3D culture systems. 
Moreover, phenotypic analysis of organoids can typically only be performed after dissociating 
the tissue, resulting in the termination of the culture, whereas in 2D cultures it is possible 
to monitor the development and activity of individual cells over time. A determination of 
the most suitable cell culture model should be based on the specific research question to 
be addressed – adding layers of complexity to a system will not necessarily improve the 
likelihood of identifying a disease associated phenotype. 
Future of in vitro brain modeling
Technical advancements in culturing protocols, standardized commercial media and 
specialized culture environments have greatly reduced the batch-to-batch variability 
associated with iPSC-derived cultures345. Due to the logistical and financial burden 
traditionally associated with iPSC-based studies, they are often underpowered to detect 
relevant cellular phenotypes346. An increase in sample size will be necessary to detect 
more subtle cellular differences in iPSC-derived cultures. The first large-scale iPSC studies 
are emerging347–349, however these studies focus on cellular variability at the pluripotent 
state. The differentiation of multiple iPSC-lines towards neural cells is a laborious and 
lengthy process, often requiring a multi-staged differentiation process and, consequently, 
careful monitoring of batch effects.  Technical advancements such as single-cell RNA 
sequencing have made it possible to differentiate and identify multiple iPSC lines in a single 
well, so called “cell villages”348, potentially reducing technical, but not biological, variation 
between lines and dramatically reducing the associated logistical burden and necessary 
infrastructure. This approach is cost-effective and allows for the identification of common 
genetic variants associated with certain cellular phenotypes350. Currently, there are a limited 
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number of functional readouts that can be acquired from these pooled cultures. Individual 
donors need to be identified based on genomic information, restricting the potential to study 
living cells or donor-autonomous effects on cellular phenotypes. Novel techniques are being 
developed to interrogate cultures with a mixed or pooled genetic background, allowing for 
the study of neural cells with different genetic signatures in a single culture dish.
Besides mixing iPSCs of multiple donors, CRISPR/Cas9 is being used to create cultures 
with a mixed genetic background from a single donor. By using sgRNA libraries, it is 
possible to target every gene in the genome or in cell type/function specific genesets351,352. 
The combination of CRISPRi/a and sgRNA libraries is being employed to perform genome-
wide screens to systematically profile gene function. A recent successful study has used this 
approach to screen for regulators of a known disease-associated protein, PARKIN353, an 
E3 ligase mutated in familial Parkinson’s disease. Using a pooled lentiviral sgRNA library, 
“cell villages” were created within a culture of HEK293 cells by knocking down single genes 
in individual cells. This screen identified regulators that influenced PARKIN protein levels; 
these were later verified in neuronal cultures. So far, very few genome-wide CRISPR screens 
have been performed to study brain disorders, likely a consequence of the substantial costs 
and time investment associated with iPSC-derived neural cultures. The first large scale 
CRISPRi screen in human iPSC-derived neurons utilized a defined sgRNA library to identify 
genes that are essential for neuronal survival354. Interestingly, follow-up single-cell RNA 
sequencing showed that knockdown of UBA1, a broadly expressed housekeeping gene, 
induced a plethora of downstream transcriptomic phenotypes in neurons, but not in iPSCs. 
Technical limitations prevent a large-scale analysis of gene-specific effects on neuronal 
functioning, since experimental readouts are needed to provide information on the genotype 
of the cells. An array approach combined with longitudinal imaging was used to look at the 
effect of 23 genes on neurite outgrowth354. This proof-of-concept screen already produced 
a wealth of data, uncovering genes that promote or hamper neurite outgrowth, providing 
insight into fundamental neurodevelopmental processes. 
Aside from their use in a disease-related context, studies using human iPSC have revealed 
a great deal about normal human brain development. Extensive genetic analysis of up to 
20-months old brain organoids revealed that iPSC-derived neural models can mature beyond 
the fetal stage and, at least partly, recapitulate the timing of human brain development355. 
These organoids follow an internal clock that synchronizes their development in the lab 
to that of human in vivo neurodevelopment. Interestingly, the developmental timing of 
human brain organoids is slower compared to macaque or chimpanzee organoids356, again 
highlighting the importance of using human cells to study human biology. Other studies 
have used human stem cells to identify human specific molecular cues involved in brain 
development. For example, human-specific NOTCH2NL genes were found to affect Notch 
signaling in radial glia and influence NPC maturation, possibly contributing to the emergence 
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of the large neocortex in humans357. Human brain evolution was studied by reintroducing 
an archaic variant of NOVA1 into human iPSCs, using these cells researchers were able 
to create “Neanderthal brain organoids”358. This single variant caused changes in splicing 
variants of genes involved in neurodevelopment, cell proliferation and synapse formation. 
Neurons in these archaic organoids showed altered network activity and changes in synaptic 
density. These studies provide insight into the genetic pathways that were involved in the 
evolution of the human brain.
Technical advances have created new opportunities to combine genetic screens with 
functional readouts. Identifying the targeted gene in individual cells currently has to be done 
based on genomic information. Through single cell RNA sequencing, the effect of such a 
mutation on the transcriptome can be studied. Functional readouts can be implemented 
before identifying the targeted gene in genome-wide screens, but these are often relatively 
basic and limited to genes related to cell survival350,354. Combining RNA sequencing and 
calcium imaging of individual cells in the developing human cortex has provided insight into 
the functional dynamics of individual cells359. At multiple timepoints during development, 
calcium dynamics of individual cells were measured in the presence of different compounds 
and followed by single cell RNA sequencing, creating a multimodal dataset for individual 
cells. Other studies have developed 3D high density multi-electrode arrays (MEA) to track 
the growth and electrical activity of neurons over time360 or expressed DNA barcodes for in 
vitro clonal lineage tracing361. Future combinations of these techniques with high content 
imaging362 and in situ sequencing363 can overcome many limitations currently associated 
with iPSC brain disease modeling. Batch-to-batch variability is less of an issue when 
the comparison is between individual cells. Clonal lineage tracing from individual iPSCs 
to mature neural cells can resolve the effect of iPSC biological heterogeneity on the 
developmental trajectory towards neural cells.
The incorporation of these modern molecular techniques to interrogate cells in vitro requires 
tailored cell culture vessels. Traditional well plates are often unsuited to perform detailed 
analysis on individual living cells. Custom devices have been designed to monitor neural cells 
during their maturation. The fabrication of these cell culture chips is a matter of significant 
biomedical engineering research364,365. Organ-on-a-chip and more specifically brain-on-a-
chip (BoC) devices can incorporate microfluidics, electrodes and 3D compartmentalized 
structures in a single translucent vessel. These chips attempt to mimic the structural and 
functional aspects of the brain in order to provide iPSC-derived neural cells with a more in 
vivo -like environment. BoC-devices try to minimize cell culture variability by more closely 
defining the environment in which the cells are grown. Combined with the ability to perform 
continuous functional readouts, their small footprint make these chips an excellent tool for 
genetic or drug screens.
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What constitutes a BoC is loosely defined, in general a cell culture vessel with an additional 
engineered feature to increase cell functioning or experimental assays is considered a 
BoC device. Microfluidics are often incorporated into BoC devices, providing additional 
control over the flow of nutrients and a more natural 3D scaffold for cells. An artificial 
model of the blood-brain-barrier can be created in such a chip in which iPSC-derived 
microvascular endothelial cells and astrocytes form a tight layer of cells separating two 
microfluidic channels366. This model recapitulates molecular, structural and functional 
blood-brain-barrier properties, including trans-endothelial electrical resistance and the 
creation of a specialized transporter barrier. Microfluidics can also be used to create 
growth factor gradients, more closely mimicking neural developmental events in vivo367. 
Other approaches make use of physical barriers to direct axonal connections between two 
MEAs in a single chip368 or recreate anatomical features of the human brain such as the 
hippocampus369 or cortical folding370. BoC devices that incorporate high density MEAs with 
optical stimulation can be used to track the migration of cells, differentiate between electrical 
signals of multiple neurons or stimulate defined clusters of neurons in a network using laser-
targeted optogenetics or direct electrical microstimulation371. On a larger scale, spinning 
bioreactors have been developed to address some of the variability observed when creating 
brain organoids337,372. These small bioreactors significantly reduce the associated costs and 
improve the functioning of neural cells in the organoid. This increases the scalability of brain 
organoid cultures and their potential for studying the effect of pharmacological compounds 
or genetic variants on complex neural networks. 
Advances in BoC models have created novel cellular models of the human brain. The 
innovation of molecular techniques to influence and monitor individual cells or complete 
neural networks have provided scientists with powerful tools to study iPSC-derived neural 
cells. Combined with forward-genetics, technical breakthroughs are providing increasingly 
robust platforms to study the effect of genetic variants on the development of cellular 





It is important to consider what it is that is being modeled when using iPSC-derived neural 
cultures to study brain disorders. From a biological perspective most individuals suffering 
from neurodevelopmental or psychiatric disorders present with almost imperceivable cellular 
phenotypes. Their symptoms are mostly behavioral and require trained physicians to be 
properly diagnosed, still leaving diagnoses subjective and complex with many overlapping 
symptoms between disorders. For all intents and purposes, the fundamental architecture of 
the brain has developed normally in the setting of psychiatric disorders. Early iPSC-studies 
successfully focused on severe monogenic disorders, using iPSC-derived neural cells to 
study the effect of a mutation on specific proteins. With increased interest in iPSC disease 
modeling, there has been an increase in reports overinterpreting findings in an attempt to 
link in vitro findings to an in vivo phenotype observed in patients. IPSC-technology has 
provided scientists with nearly limitless access to living brain tissue to manipulate and study, 
and increasingly advanced protocols for directed differentiation.  Therefore, it is critical for 
the field to focus on the question of how can brain disorders be most optimally studied 
and attempt to create the most faithful representation of a human brain in vitro. Although 
protocols will continue to improve, it is unlikely that it will become possible to recreate a 
human brain in a dish without crossing ethical boundaries. Increasing knowledge on the 
etiology of human brain disorders will require researchers who perform iPSC-based studies 
to utilize data from other fields of research to formulate a defined hypothesis and adopt the 
proper model to efficiently answer these questions. The broad adaptation of iPSCs into all 
fields of human biology has accelerated the development of tools available to researchers. 
Combining disciplines will further elucidate the processes involved in the development of 
the healthy and diseased human brain, and hopefully provide novel treatments for patients 



















Induced pluripotent stem cell (iPSC)-technology has created the ability to study the 
development of patient-derived neural cells in vitro and identify cellular phenotypes. The 
potential of this relatively new field has sparked great interest in the field of neuroscience 
and beyond. The work presented in this thesis attempts to improve the techniques to 
differentiate iPSCs towards cells of the neural lineage and demonstrates how these cells 
can be leveraged to study brain disorders. We describe a protocol to generate functional 
astrocytes that are able to support the development and maturation of neural networks, 
creating the opportunity to study completely human astrocyte and neuron co-cultures. 
Patient-derived iPSCs are used for an in vivo preclinical screening of human antisense 
oligonucleotide therapy to treat Angelman Syndrome, restoring the expression of the 
causal gene defect in neurons. By performing genetic analysis on a family with a high 
incidence of schizophrenia and creating iPSCs from affected and unaffected siblings, we 
were able to identify a causative variant highly expressed in oligodendrocyte precursor 
cells, and show that these cells, when derived from patients, were less likely to mature into 
myelinating oligodendrocytes. The value of having quick access to iPSC-derived neural 
cells is demonstrated in our work with Severe Acute Respiratory Syndrome Coronavirus-2 
(SARS-CoV-2), the virus responsible for the current pandemic. Patients often experience 
neurological symptoms during or following infection. We show that although SARS-CoV-2 
primarily infects neurons, it displays limited replication in neural cultures but does induce the 
production of pro-inflammatory cytokines. Together, iPSC technology has provided novel 




De techniek om geïnduceerde pluripotente stamcellen (iPSC) te maken heeft de 
mogelijkheid gecreëerd om de ontwikkeling van patiënt-afgeleide neurale cellen te 
bestuderen in vitro en om mogelijke cellulaire fenotypes te identificeren. Dit relatief nieuwe 
onderzoeksveld heeft veel potentie en wordt daarom met veel interesse gevolgd door 
hersenwetenschappers. Het werk dat wordt beschreven in dit proefschrift doet een poging 
om de bestaande technieken voor iPSC differentiatie naar neurale cellen te verbeteren en 
laat zien hoe deze technieken gebruikt kunnen worden om hersenziekten te bestuderen. 
We beschrijven een nieuw protocol om functionele astrocyten te maken van iPSCs die de 
ontwikkeling en maturatie van neurale netwerken ondersteunen. Dit maakt het mogelijk 
om volledig humane co-culturen van neuronen en astrocyten te bestuderen. IPSCs van 
Angelman syndroom patiënten worden gebruikt voor een in vivo preklinische screening van 
een humaan-specifieke antisense oligonucleotiden therapie, hiermee is het mogelijk om 
alleen in neuronen de expressie van het causatieve gen voor deze ziekte te herstellen. Door 
genetische analyse uit te voeren binnen een familie met een hoge incidentie van schizofrenie 
en iPSCs te maken van zieke en gezonde familieleden hebben we een genetische variant 
geïdentificeerd die hoog tot expressie komt in de voorlopercellen van oligodendrocyten. 
Deze cellen ontwikkelen zich minder goed tot myeliniserende oligodendrocyten als ze 
gemaakt worden van patiënt-afgeleide iPSCs. Dat het hebben van snelle toegang tot iPSC-
afgeleide neurale cellen zeer waardevol is werd duidelijk door ons werk met Severe Acute 
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), het virus verantwoordelijk voor de 
huidige pandemie. We laten zien dat SARS-CoV-2 vooral neuronen infecteert, dat het 
zich daar slecht kan repliceren, maar wel de productie van pro-inflammatoire cytokines 
induceert. Alles bij elkaar genomen heeft de iPSC techniek nieuwe inzichten opgeleverd 
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